documents incorporated referenceparts iii portions registrants proxy statement annual meeting shareholders filed within days close registrants fiscal year proxy statement incorporated reference report reportitem part business general segments business geographic areas raw materials patents trademarks seasonality competition research development environment regulation available information risk factors b unresolved staff comments properties legal proceedings mine safety disclosures executive officers registrant part ii market registrants common equity related stockholder matters issuer purchases equity securities selected financial data managements discussion analysis financial condition results operations quantitative qualitative disclosures market risk financial statements supplementary data changes disagreements accountants accounting financial disclosure controls procedures b information part iii directors executive officers corporate governance executive compensation security ownership certain beneficial owners management related stockholder matters certain relationships related transactions director independence principal accountant fees services part iv exhibits financial statement schedules signatures exhibit index part item business general johnson johnson subsidiaries company approximately employees worldwide engaged research development manufacture sale broad range products health care field johnson johnson holding company operating companies conducting business virtually countries world companys primary focus products related human health wellbeing johnson johnson incorporated state new jersey executive committee johnson johnson principal management group responsible strategic operations allocation resources company committee oversees coordinates activities company 's three business segments consumer pharmaceutical medical devices within strategic parameters provided committee senior management groups us international operating companies responsible strategic plans daytoday operations companies subsidiary within business segments limited exceptions managed residents country located segments business company organized three business segments consumer pharmaceutical medical devices additional information required item incorporated herein reference narrative tabular descriptions segments operating results item managements discussion analysis results operations financial condition report note segments business geographic areas notes consolidated financial statements included item report consumer consumer segment includes broad range products used baby care oral care skin care overthecounter pharmaceutical womens health wound care markets baby care includes johnsons line products oral care includes listerine product line major brands skin care include aveeno clean clear dabao johnsons adult le petite marseillais lubriderm neutrogena roc product lines overthe counter medicines include broad family tylenol acetaminophen products sudafed cold flu allergy products benadryl zyrtec allergy products motrin ib ibuprofen products pepcid line heartburn products major brands womens health outside north america stayfree carefree sanitary pads ob tampon brands wound care brands include bandaid brand adhesive bandages neosporin first aid product lines products marketed general public sold retail outlets distributors throughout world pharmaceutical pharmaceutical segment focused five therapeutic areas immunology eg rheumatoid arthritis inflammatory bowel disease psoriasis infectious diseases vaccines eg hiv hepatitis respiratory infections tuberculosis neuroscience eg alzheimer 's disease mood disorders schizophrenia oncology eg prostate cancer hematologic malignancies lung cancer cardiovascular metabolic diseases eg thrombosis diabetes products segment distributed directly retailers wholesalers hospitals health care professionals prescription use key products pharmaceutical segment include remicade infliximab treatment number immunemediated inflammatory diseases simponi golimumab subcutaneous treatment adults moderate severe rheumatoid arthritis active psoriatic arthritis active ankylosing spondylitis moderately active severely active ulcerative colitis simponi aria golimumab intravenous treatment adults moderate severe rheumatoid arthritis stelara ustekinumab treatment adults moderate severe plaque psoriasis active psoriatic arthritis adolescents moderate severe psoriasis olysiosovriadsimeprevir combination treatment chronic hepatitis c adult patients prezista darunavir edurant rilpivirine prezcobixrezolsta darunavircobicistat antiretroviral medicines treatment human immunodeficiency virus hiv combination antiretroviral products sirturo bedaquiline diarylquinoline antimycobacterial drug indicated part combination therapy adults years pulmonary multidrug resistant tuberculosis mdrtb concerta methylphenidate hcl extended release tablets cii treatment attention deficit hyperactivity disorder invega paliperidone extendedrelease tablets treatment schizophrenia schizoaffective disorder invega sustennaxeplion paliperidone palmitate treatment schizophrenia schizoaffective disorder adults invega trinza paliperidone palmitate treatment schizophrenia patients adequately treated invega sustenna least four months risperdal consta risperidone longacting injection treatment ofschizophrenia maintenance treatment bipolar disorder adults velcade bortezomib treatment multiple myeloma use combination rituximab cyclophosphamide doxorubicin prednisone treatment adult patients previously untreated mantle cell lymphoma zytiga abiraterone acetate used combination prednisone treatment metastatic castrationresistant prostate cancer imbruvica ibrutinib oral oncedaily therapy approved use treating certain bcell malignancies blood cancers waldenstrm 's macroglobulinemia darzalextm daratumumab treatment double refractory multiple myeloma yondelis trabectedin treatment patients unresectable metastatic liposarcoma leiomyosarcoma received prior anthracycline containing regimen procrit epoetin alfa sold outside us eprex stimulate red blood cell production xarelto rivaroxaban oral anticoagulant prevention deep vein thrombosis dvt may lead pulmonary embolism pe patients undergoing hip knee replacement surgery reduce risk stroke systemic embolism patients nonvalvular atrial fibrillation treatment reduction risk recurrence dvt pe invokana canagliflozin treatment adults type diabetes invokametvokanamet canagliflozinmetformin hcl combination therapy fixed doses canagliflozin metformin hydrochloride treatment adults type diabetes many medicines developed collaboration strategic partners licensed companies maintain active lifecycle development programs medical devices medical devices segment includes broad range products used orthopaedic surgery cardiovascular diabetes care vision care fields products distributed wholesalers hospitals retailers used principally professional fields physicians nurses hospitals eye care professionals clinics include orthopaedic products general surgery biosurgical endomechanical energy products electrophysiology products treat cardiovascular disease sterilization disinfection products reduce surgical infection diabetes care products blood glucose monitoring insulin delivery products disposable contact lenses geographic areas business johnson johnson conducted operating companies located countries including us virtually countries throughout world products made sold international business include many described segments business consumer pharmaceutical medical devices however principal markets products methods distribution international business vary country culture products sold international business include developed united states subsidiaries abroad investments activities countries outside us subject higher risks comparable us activities investment commercial climate may influenced financial instability international economies restrictive economic policies political legal system uncertainties raw materials raw materials essential company 's business generally readily available multiple sources exceptions temporary unavailability raw materials would likely material adverse effect financial results company patents company 's subsidiaries made practice obtaining patent protection products processes possible licensed number patents relating products manufacturing processes aggregate believed material importance company operation businesses sales companys largest product remicade infliximab accounted approximately company 's total revenues fiscal accordingly patents related product believed material company two sets patents related specifically remicade infliximab first set patents coowned janssen biotech inc whollyowned subsidiary johnson johnson nyu langone medical center nyu janssen biotech inc exclusive license nyu 's interests patents patents expired countries outside united statesin united states latest patents expires september patent stands rejected subject reexamination proceedings instituted third party united states patent trademark office proceedings going second set patents specifically related remicade granted kennedy institute rheumatology europe canada australia united states janssen biotech inc licenses exclusive human antitnf antibodiesand semiexclusive nonhuman antitnf antibodies patents expire outside united states united states validity patents challenged certain claims invalidated others review various patent offices around world also subject litigation canada company expect additional extensions available described patents specifically related remicade remicade related patents discussed found invalid patent could relied upon prevent introduction biosimilar versions remicade extensive description legal matters regarding patents related remicade see note legal proceedings intellectual property pharmaceutical remicaderelated cases notes consolidated financial statements included item report addition competing immunology market remicade company currently marketing stelara ustekinumab simponi golimumab simponi aria golimumab next generation immunology products remaining patent lives eight years trademarks companys subsidiaries made practice selling products trademarks obtaining protection trademarks available means trademarks protected registration united states countries products marketed company considers trademarks aggregate material importance operation businesses seasonality worldwide sales reflect significant degree seasonality however spending heavier fourth quarter year quarters reflects increased spending decisions principally advertising research development activity competition product lines company 's subsidiaries compete companies locally globally competition exists product lines without regard number size competing companies involved competition research internally externally sourced involving development improvement new existing products processes particularly significant development new innovative products well protecting underlying intellectual property companys product portfolio important company 's success areas business competitive environment requires substantial investments continuing research addition development maintenance customer demand companys consumer products involve significant expenditures advertising promotion research development research activities represent significant part companys businesses research development expenditures relate processes discovering testing developing new products improving existing products well demonstrating product efficacy regulatory compliance prior launch company remains committed investing research development aim delivering high quality innovative products worldwide costs research development activities amounted billion billion billion fiscal years respectively research facilities located united states belgium brazil canada china france germany india israel japan netherlands singapore switzerland united kingdom environment company subject variety us international environmental protection measures company believes operations comply material respects applicable environmental laws regulations companys compliance requirements change past year expected material effect upon capital expenditures cash flows earnings competitive position regulation companys businesses subject varying degrees governmental regulation countries operations conducted general trend toward increasingly stringent regulation us drug device cosmetic industries long subject regulation various federal state agencies primarily product safety efficacy manufacturing advertising labeling safety reporting exercise broad regulatory powers us food drug administration fda continues result increases amounts testing documentation required forfda approval new drugs devices corresponding increase expense product introduction similar trends also evident major markets outside us costs human health care continue subject study investigation regulation governmental agencies legislative bodies around world us attention focused drug prices profits programs encourage doctors write prescriptions particular drugs recommend use purchase particular medical devices payers become potent force market place increased attention paid drug medical device pricing appropriate drug medical device utilization quality costs health care generally us government agencies continue implement extensive requirements patient protection affordable care act aca positive negative impacts us healthcare industry much remaining uncertain various provisions aca ultimately affect industry regulatory agencies whose purview company operates administrative powers may subject actions product withdrawals recalls seizure products civil criminal sanctions cases companys subsidiaries may deem advisable initiate product recalls addition business practices health care industry come increased scrutiny particularly united states government agencies state attorneys general resulting investigations prosecutions carry risk significant civil criminal penalties company relies global supply chains production distribution processes complex subject increasing regulatory requirements may affect sourcing supply pricing materials used company 's products processes also subject lengthy regulatory approvals available information companys main corporate website address wwwjnjcom copies companys quarterly reports form q annual report current reports form k filed furnished us securities exchange commission sec amendments foregoing provided without charge shareholder submitting written request secretary principal executive offices company calling companys sec filings also available companys website wwwinvestorjnjcomgovsecfilingscfm soon reasonably practicable electronically filed furnished sec sec filings also available secs website wwwsecgov addition written charters audit committee compensation benefits committee nominating corporate governance committee regulatory compliance government affairs committee science technology sustainability committee board directors companys principles corporate governance code business conduct employees code business conduct ethics members board directors executive officers corporate governance materials available wwwinvestorjnjcomgov materialscfm company 's website provided without charge shareholder submitting written request provided information companys website deemed part report incorporated filings company makes sec item risk factors company faces number uncertainties risks difficult predict many outside company 's control addition information report companys filings sec investors consider carefully factors set forth exhibit report investors realize known unknown risks uncertainties materialize companys business results operations financial condition could adversely affected item b unresolved staff comments applicable item properties company 's subsidiaries operate manufacturing facilities occupying approximately million square feet floor space manufacturing facilities used industry segments companys business approximately follows square feet segment thousands consumer pharmaceutical medical devices worldwide total within united states eight facilities used consumer segment eight pharmaceutical segment medical devices segment outside united states facilities used consumer segment pharmaceutical segment medical devices segment locations manufacturing facilities major geographic areas world follows number square feet geographic area facilities thousands united states europe western hemisphere excluding us africa asia pacific worldwide total addition manufacturing facilities discussed company maintains numerous office warehouse facilities throughout world research facilities also discussed item report business research development company 's subsidiaries generally seek manufacturing facilities although principally nonus locations leased office warehouse facilities often leased company also engages contract manufacturers company committed maintaining properties good operating condition repair facilities well utilized mcneilppc inc johnson johnson consumer inc mcneilppc continues operate consent decree signed fda governs certain mcneil consumer healthcare manufacturing operations requires mcneilppc remediate facilities operates lancaster pennsylvania fort washington pennsylvania las piedras puerto rico consent decree fort washington facility voluntarily shut april subsequently many products transferred manufacturing sites successfully reintroduced market mcneilppc successfully completed requirements contained consent decree workplans lancaster las piedras manufacturing sites completed steps required thirdparty certification fort washington plant thirdparty cgmp expert submitted written certifications fda three manufacturing sites following fda inspections mcneilppc received notifications fda three manufacturing facilities conformity applicable laws regulations commercial production fort washington started september consent decree receiving notice fda compliance applicable laws regulations three facilities subject fiveyear audit period thirdparty cgmp expert thus thirdparty expert continue reassess sites various times least five years discussion legal proceedings related matter found note legal proceedings government proceedings mcneil consumer healthcare notes consolidated financial statements included item report information regarding lease obligations see note rental expense lease commitments notes consolidated financial statements included item report segment information additions property plant andequipment contained note segments business geographic areas notes consolidated financial statements included item report item legal proceedings information called item incorporated herein reference information set forth note legal proceedings notes consolidated financial statements included item report addition johnson johnson subsidiaries time time party government investigations inspections proceedings relating environmental matters including compliance applicable environmental laws item mine safety disclosures applicable executive officers registrant listed executive officers company february family relationships executive officers arrangement understanding executive officer person pursuant executive officer selected annual meeting board directors executive officers elected board hold office one year respective successors elected qualified earlier resignation removal information regard directors company including information alex gorsky incorporated herein reference material captioned item election directors proxy statement name age position dominic j caruso member executive committee vice president finance chief financial officera peter fasolo member executive committee vice president global human resourcesb alex gorsky chairman board directors chairman executive committee chief executive officer sandra e peterson member executive committee group worldwide chairmanc paulus stoffels member executive committee chief scientific officer worldwide chairman pharmaceuticalsd michael h ullmann member executive committee vice president general counsele mr j caruso joined company company acquired centocor inc time acquisition senior vice president finance centocor mr caruso named vice president finance orthomcneil pharmaceutical inc subsidiary company vice president group finance companys medical devices diagnostics group mr caruso named vice president companys group finance organization mr caruso became member executive committee vice president finance chief financial officer b dr p fasolo joined company vice president worldwide human resources cordis corporation subsidiary company named vice president global talent management company left johnson johnson join kohlberg kravis roberts co chief talent officer dr fasolo returned company vice president global human resources became member executive committee c ms e peterson joined company group worldwide chairman member executive committee responsibility consumer group companies consumer medical device businesses vision care diabetes care franchises functions johnson johnson supply chain information technology wellness prevention global strategic design prior joining johnson johnson ms peterson extensive global career healthcare consumer goods consulting recently chairman chief executive officer bayer cropscience ag germany previously serving president chief executive officer bayer medical care president bayer healthcare ag 's diabetes care division joining bayer ms peterson held number leadership roles medco health solutions previously known merckmedco among responsibilities application information technology healthcare systems dr p stoffels joined company acquisition virco tibotec chief executive officer virco chairman tibotec appointed company group chairman global virology led development prezista intelence leading products treatment hiv assumed role company group chairman pharmaceuticals responsibility worldwide research development central nervous system internal medicine franchises dr stoffels appointed global head research development pharmaceuticals became worldwide chairman pharmaceuticals responsibility company 's therapeutic pipeline global research development strategic business development dr stoffels also appointed chief scientific officer responsibility enterprisewide innovation product safety member executive committee e mr h ullmann joined company corporate attorney law department appointed corporate secretary served role time also held various management positions law department named general counsel medical devices diagnostics mr ullmann appointed vice president general counsel member executive committee part ii item market registrants common equity related stockholder matters issuer purchases equity securities february record holders common stock company additional information called item incorporated herein reference following sections report item managements discussion analysis results operations financial condition liquidity capital resources dividends information common stock market prices note common stock stock option plans stock compensation agreements notes consolidated financial statements included item item security ownership certain beneficial owners management related stockholder matters equity compensation plan information issuer purchases equity securities october company announced board directors approved share repurchase program authorizing company purchase billion company 's common stock share repurchases take place open market time time based market conditions repurchase program time limit may suspended periods discontinued time following table provides information respect common stock purchases company fiscal fourth quarter common stock purchases open market made part systematic plan meet needs companys compensation programs repurchases also include stockforstock option exercises settled fiscal fourth quarter total number maximum number shares units approximate dollar purchased value shares total number part publicly units may yet shares avg price announced plans purchased period purchased paid per share programs plans programs september october october november november january total fiscal fourth quarter company repurchased aggregate shares johnson johnson common stock openmarket transactions shares purchased pursuant repurchase program publicly announced october shares purchased openmarket transactions part systematic plan meet needs companys compensation programs january aggregate shares purchased total billion since inception repurchase program announced october january maximum number shares may yet purchased plan based closing price johnson johnson common stock new york stock exchange december per shareitem selected financial data summary operations statistical data dollars millions except per share amounts sales customers us sales customers international total sales cost products sold selling marketing administrative expenses research development expense inprocess research development interest income interest expense net portion capitalized income expense net restructuring earnings provision taxes income provision taxes income net earnings add net loss attributable noncontrolling interest net earnings attributable johnson johnson percent sales customers diluted net earnings per share common stock percent return average shareholders equity percent increase decrease previous year sales customers diluted net earnings per share supplementary balance sheet data property plant equipment net additions property plant equipment total assets longterm debt operating cash flow common stock information dividends paid per share shareholders equity per share market price per share yearend close average shares outstanding millions basic diluted employees thousands attributable johnson johnson amounts reclassified conform current year presentation item managements discussion analysis results operations financial condition organization business segments description company business segments johnson johnson subsidiaries company approximately employees worldwide engaged research development manufacture sale broad range products health care field company conducts business virtually countries world primary focus products related human health wellbeing company organized three business segments consumer pharmaceutical medical devices consumer segment includes broad range products used baby care oral care skin care overthecounter pharmaceutical womens health wound care markets products marketed general public sold retail outlets distributors throughout world pharmaceutical segment focused five therapeutic areas including immunology infectious diseases neuroscience oncology cardiovascular metabolic diseases products segment distributed directly retailers wholesalers hospitals health care professionals prescription use medical devices segment includes broad range products used orthopaedic surgery cardiovascular diabetes care vision care fields distributed wholesalers hospitals retailers used principally professional fields physicians nurses hospitals eye care professionals clinics executive committee johnson johnson principal management group responsible strategic operations allocation resources company committee oversees coordinates activities consumer pharmaceutical medical devices business segments product lines company competes companies locally globally throughout world competition exists product lines without regard number size competing companies involved competition research involving development improvement new existing products processes particularly significant development new innovative products well protecting underlying intellectual property company 's product portfolio important companys success areas business competitive environment requires substantial investments continuing research addition development maintenance customer demand companys consumer products involves significant expenditures advertising promotion managements objectives company manages within strategic framework credo foundation company believes strategic operating principles broadly based human health care managing business long term decentralized management approach committed people values crucial successfully meeting demands rapidly evolving markets compete end management focused longterm strategic growth drivers creating value innovation expanding global reach local focus excellence execution leading purpose company broadly based human health care committed creating value developing accessible high quality innovative products services new products introduced within past five years accounted approximately sales billion sales invested research development reflecting managements commitment delivering new differentiated products services meet evolving health care needs sustain companys longterm growth diverse businesses operating companies located countries key drivers companys success maintaining companys decentralized management approach time leveraging extensive resources enterprise positions company well innovate execute strategic plans reach markets globally well address needs challenges local markets order remain leader health care company strives maintain purposedriven organization committed developing global business leaders achieve growth objectives businesses managed longterm order sustain market leadership positions enable growth provides enduring source value shareholders credo unifies johnson johnson employees achieving objectives provides common set values serve foundation companys responsibilities patients consumers health care professionals employees communities shareholders company believes foundational values strategic framework longterm growth drivers along overall mission improving quality life people around world enable johnson johnson continue leader health care industryresults operations analysis consolidated sales worldwide sales decreased billion compared increases sales changes consisted following sales increasedecrease due volume price currency total introduction competitive products company 's hepatitis c products olysiosovriad simeprevir incivo telaprevir negative impact worldwide operational sales growth impact acquisitions divestitures worldwide operational sales growth negative sales company 's hepatitis c products olysiosovriad simeprevir incivo telaprevir positive impact divestiture orthoclinical diagnostics business negative impact worldwide operational growth acquisition synthes inc net related divestiture increased worldwide operational growth sales us companies billion billion billion represents increases sales international companies billion billion billion represents decrease increases fiveyear compound annual growth rates worldwide us international sales respectively tenyear compound annual growth rates worldwide us international sales respectively sales companies europe experienced decline compared prior year including operational growth offset negative currency impact sales companies western hemisphere excluding us experienced decline compared prior year including operational growth offset negative currency impact sales companies asiapacific africa region experienced decline compared prior year including operational growth negative currency impact results benefited inclusion rd week see note consolidated financial statements annual closing date details company estimated fiscal year growth rate enhanced approximately additional week added days sales also added full week 's worth operating costs therefore net earnings impact negligible company one wholesaler distributing products three segments represented approximately respectively total consolidated revenues company customer represented total consolidated revenues us health care reform july internal revenue service issued final regulations branded prescription drug fee annual nontax deductible fee imposed entities engaged business manufacturing importing branded prescription drugs covered entities enacted section patient protection affordable care act final regulations accelerated expense recognition criteria fee obligation one year year fee paid year sales used calculate fee occur change impacted covered entities resulted need entities record additional expense fee would otherwise expensed paid company accrued additional million fiscal third quarter due change fee associated accelerated expense paid scheduled cash impact analysis sales business segments consumer segment consumer segment sales billion decrease included operational growth offset negative currency impact us consumer segment sales billion increase international sales billion decrease included operational growth offset negative currency impact divestitures negative impact worldwide consumer segment operational growth major consumer franchise sales change dollars millions vs vs otc skin care baby care oral care womens health wound careother total consumer sales overthecounter otc franchise sales billion decreased compared prior year included operational growth negative currency impact operational growth primarily driven analgesics upper respiratory including zyrtecand digestive health products mcneilppc inc johnson johnson consumer inc mcneilppc continues operate consent decree signed us food drug administration fda governs certain mcneil consumer healthcare manufacturing operations requires mcneilppc remediate facilities operates lancaster pennsylvania fort washington pennsylvania las piedras puerto rico consent decree february thirdparty expert submitted written certification fda three manufacturing sites following fda inspections mcneilppc received notifications fda three manufacturing facilities conformity applicable laws regulations consent decree receiving notice fda compliance applicable laws regulations three facilities subject fiveyear audit period thirdparty cgmp expert thus thirdparty expert continue reassess sites various times least five years skin care franchise sales billion decreased compared prior year included operational growth negative currency impact operational growth primarily due sales growth neutrogena aveeno products partially offset lower sales china baby care franchise sales billion decrease compared prior year included operational growth negative currency impact operational growth primarily due new product launches partially offset competition china oral care franchise sales billion decrease compared prior year included operational growth negative currency impact operational growth driven increased sales listerine productsattributable geographical expansion new products successful marketing campaigns womens health franchise sales billion decrease compared prior year included operational growth negative currency impact operational growth outside us driven new product launches successful marketing campaigns wound careother franchise sales billion decrease primarily due splenda andbenecol divestitures consumer segment sales billion decrease included operational growth offset negative currency impact us consumer segment sales billion decrease international sales billion decrease included operational growth offset negative currency impact pharmaceutical segment pharmaceutical segment sales billion decrease included operational growth offset negative currency impact us sales billion increase international sales billion decrease included operational growth offset negative currency impact pharmaceutical segment operational growth negatively impacted due introduction competitive products company 's hepatitis c products olysiosovriad simeprevir incivo telaprevir positively impacted due adjustment previous reserve estimates including managed medicaid rebates primarily cardiovascularmetabolismother therapeutic area divestitures negative impact worldwide pharmaceutical segment operational growth major pharmaceutical therapeutic area sales change vs vs dollars millions total immunology remicade simponisimponi aria stelara immunology total infectious diseases edurant olysiosovriad prezista prezcobixrezolsta infectious diseases total neuroscience concertamethylphenidate invegapaliperidone invega sustennaxeplioninvega trinza risperdal consta neuroscience total oncology imbruvica velcade zytiga oncology cardiovascular metabolism xarelto invokana invokamet procriteprex total pharmaceutical sales prior year amounts reclassified conform current year presentation percentage greater previously referred immunology products achieved sales billion representing increase compared prior yearimmunology products growth included operational growth negative currency impact increased sales stelara ustekinumab simponisimponiaria golimumab due market growth increased penetration simponi aria growth partially offset lower remicade infliximab salesto company 's distributor primarily due weakening euro biosimilar competition europe patents remicade certain countries europe expired february biosimilar versions remicade introduced certain markets outside united states resulting reduction sales remicade markets additional biosimilar competition likely result reduction remicade sales markets outside united states timing possible introduction biosimilar version remicade united states subject enforcement patent rights approval fda compliance day notice provisions biologics price competition innovation act bpcia february arthritis advisory committee fda recommended vote approve first investigational biosimilar infliximab across eligible indications united states risk competitor could launch biosimilar version remicade following fda approval subject compliance day notice provisions bpcia even though one valid patents place introduction us market biosimilar version remicade result reduction us sales remicade us sales remicade billion launch biosimilar version remicade us expected material adverse effect companys results operations cash flows see note consolidated financial statements legal matters regarding remicade patents infectious disease products sales billion decline included operational decrease negative currency impact competitive products company 's hepatitis c products olysiosovriad simeprevir incivo telaprevir significant negative impact us sales continue negative impact future sales decline hepatitis c sales partially offset sales growth edurantrilpivirine sales prezista prezcobixrezolsta darunavircobicistat neuroscience products sales billion decrease included operational growth negative currency impact us sales growth concertamethylphenidate primarily due therapeutic equivalence reclassification generic competitors fda november strong sales invega sustennaxeplioninvega trinza paliperidone palmitate primarily due increased market share launch invega trinza neuroscience products sales negatively impacted us divestiture nucynta tapentadol lower sales risperdal consta risperidone oncology products achieved sales billion representing increase compared prior year oncology products growth included operational growth negative currency impact contributors growth strong sales imbruvica ibrutinib due approval new indications additional country launches strong patient uptake additionally sales zytiga abiraterone acetate grew us due market growth partially offset share decline strong growth asia latin america partially offset lower sales europe due competition cardiovascularmetabolismother products achieved sales billion representing increase compared prior year due strong sales xareltorivaroxaban invokanainvokamet canagliflozin procriteprex epoetin alfa sales impacted competition company advanced pipeline several regulatory submissions approvals new drugs additional indications existing drugs follows us eu us eu product name chemical name indication approv approv filing filing treatment double refractory multiple darzalex daratumumab myeloma use combination antiretroviral agents treatmentnave adolescent patients edurant rilpiravine aged years hiv infection imbruvica ibrutinib treatment waldenstrm 's macroglobulinemia treatment patients relapsed refractory chronic lymphocytic leukemia cll small lymphocytic lymphoma combination bendamustine rituximab use treatmentnave patients chronic lymphocytic leukemia invega trinza paliperidone atypical antipsychotic injection administered four palmitate times year treatment schizophrenia oncedaily therapy combining fixed doses canagliflozin metformin hydrochloride extended release treatment adults type invokamet xr canagliflozin diabetes use combination antiretroviral medicinal products treatment human prezcobix darunavircobicistatimmunodeficiency virus hiv simponi golimumab treatment nonradiographic axial spondyloarthritis treatment adolescents moderate stelara ustekinumab tosevere psoriasis treatment adult patients moderately severely active crohn 's disease use combination rituximab cyclophosphamide doxorubicin prednisone treatment adult patients previously velcade bortezomib untreated mantle cell lymphoma treatment patients unresectable yondelis trabectedin metastatic liposarcoma leiomyosarcoma pharmaceutical segment achieved sales billion representing increase prior year strong operational growth negative currency impact us sales billion increase international sales billion increase included operational growth negative currency impact pharmaceutical segment sales included positive adjustment previous estimates managed medicaid rebates negatively impacted pharmaceutical operational sales growth compared prior year sales company 's hepatitis c products olysiosovriad simeprevir incivo telaprevir positive impact operational growth pharmaceutical segment medical devices segment medical devices segment sales billion decrease included operational decline negative currency impact us sales billion decrease compared prior year international sales billion decrease compared prior year operational decrease negative currency impact divestitures orthoclinical diagnostics cordis businesses negative impact respectively worldwide operational growth medical devices segment compared major medical devices franchise sales change dollars millions vs vs orthopaedics hips knees trauma spine surgery advanced general specialty vision care cardiovascular diabetes care diagnostics total medical devices sales prior year amounts reclassified conform current year presentation orthopaedics franchise sales billion decrease included operational growth negative currency impact operational growth us europe regions primarily driven sales hip primary stem platform attune knee system trauma tfna nailing system sports medicine orthoviscmonovisc products growth negatively impacted softer demand reduction customer inventory levels primarily china continued pricing pressures surgery franchise sales billion decrease included operational growth negative currency impact operational growth advanced surgery driven endocutter biosurgical energy products primarily attributable market growth increased penetration certain markets new product launches operational growth specialty surgery primarily driven mentor products growth partially offset lower sales women 's health urology products general surgery vision care franchise sales billion decrease included operational growth negative currency impact operational growth major regions primarily driven new product launches partially offset lower price cardiovascular franchise sales billion decrease represented operational decline negative currency impact strong operational growth electrophysiology business driven market growth success thermocool smarttouchcatheter offset impact divesting cordis business company completed divestiture cordis business cardinal health october cordis business generated annual net revenues approximately million million respectively additional details see note consolidated financial statements diabetes care franchise sales billion decrease represented operational decline negative currency impact operational decline primarily due lower price partiallyoffset success animas vibe products june company divested orthoclinical diagnostics business diagnostics franchise carlyle group additional details see note consolidated financial statements medical devices segment sales billion decrease included operational decline negative currency impact us sales billion decrease compared prior year international sales billion decline compared prior year operational growth offset negative currency impact divestiture orthoclinical diagnostics business negative impact operational growth medical devices segment analysis consolidated earnings provision taxes income consolidated earnings provision taxes income decreased billion compared billion decrease decrease primarily attributable significantly lower sales olysiosovriad simeprevir negative currency impacts restructuring charge billion higher intangible asset writedowns billion compared decrease partially offset lower net litigation expense billion lower synthes integration costs billion positive adjustment billion previous reserve estimates including managed medicaid rebates higher gains billion divestitures compared prior year fiscal year included higher gains billion primarily divestitures cordis business splenda brand us divestiture nucynta versus gains recorded divestitures orthoclinical diagnostics business ky brand additionally included additional year branded prescription drug fee billion consolidated earnings provision taxes income increased billion compared billion increase earnings provision taxes income favorable due strong sales volume growth particularly sales olysiosovriad simeprevir positive mix higher sales higher margin products pharmaceutical business divestitures lower margin businesses cost reduction efforts across many businesses additionally included higher net gains divestitures billion primarily divestiture orthoclinical diagnostics business lower litigation expense billion lower inprocess research development costs billion lower expenses billion related depuy asr hip program compared fiscal year partially offset inclusion additional year branded prescription drug fee billion billion higher synthes integrationtransaction costs fiscal year included net gain billion equity investment transactions primarily sale elan american depositary shares percent sales consolidated earnings provision taxes income versus cost products sold selling marketing administrative expenses cost products sold selling marketing administrative expenses percent sales follows sales cost products sold percent point increasedecrease prior year selling marketing administrative expenses percent point increasedecrease prior year cost products sold percent sales increased slightly compared prior year favorable mix segments offset million associated restructuring activity medical devices segment negative transactional currency lower sales olysiosovriad simeprevir intangible asset amortization expense included cost products sold billion billion respectively increase percent sales selling marketing administrative expenses compared prior year primarily due incremental investment spending segments impact lower sales olysiosovriad simeprevir partially offset favorable mix inclusion additional year branded prescription drug fee billion cost products sold percent sales decreased compared prior year primarily result positive mix higher sales higher margin products pharmaceutical business divestitures lower margin businesses cost improvements across many businesses partially offset pricing impact negative transactional currency addition included inventory stepup charge billion related synthes acquisition intangible asset amortization expense included cost products sold billion decrease percent sales selling marketing administrative expenses compared prior year primarily due leveraged costs resulting growth pharmaceutical business particularly sales olysiosovriad simeprevir cost containment initiatives across many businesses partially offset inclusion additional year branded prescription drug fee million fiscal third quarter research development expense research development expense segment business follows dollars millions amount sales amount sales amount sales consumer pharmaceutical medical devices total research development expense percent increasedecrease prior year percent segment sales research development activities represent significant part company 's business expenditures relate processes discovering testing developing new products upfront payments milestones improving existing products well ensuring product efficacy regulatory compliance prior launch company remains committed investing research development aim delivering high quality innovative products worldwide costs research development activities increased compared increase percent sales attributable increased investment spending primarily pharmaceutical segment lower overall sales business mix worldwide costs research development activities increased compared reduction percent sales primarily due strong sales growth pharmaceutical business research spending pharmaceutical segment increased absolute dollars billion compared billion primarily due higher levels spending advance company 's pharmaceutical pipeline inprocess research development iprd company recorded iprd charge billion primarily discontinuation certain development projects related covagen company recorded iprd charge billion impairment various iprd projects related respivert crucell mentor synthes delay discontinuation certain development projects company recorded iprd charge billion primarily impairment various iprd projects related crucell corimmun acclarent delay discontinuation certain development projects income expense net income expense net account company records gains losses related sale writedown certain investments equity securities held johnson johnson innovation jjdc inc formerly johnson johnson development corporation gains losses divestitures transactional currency gains losses acquisitionrelated costs litigation accruals settlements well royalty income change income expense net fiscal year favorable change billion compared prior year primarily due lower litigation expense billion lower synthes integration costs billion higher jjdc portfolio gains billion compared prior year additionally fiscal year included higher gains billion primarily divestitures cordis business splenda brand us divestiture nucynta versus gains recorded divestitures orthoclinical diagnostics business ky brand partially offset higher intangible asset writedowns billion change income expense net fiscal year favorable change billion compared prior year fiscal year included higher net gains divestitures billion primarily divestiture ortho clinical diagnostics business lower litigation expense billion lower costs billion related depuy asr hip program compared partially offset higher synthes integrationtransaction costs billion higher intangible asset writedowns billion primarily related incivo telaprevir additionally fiscal year included higher net gain billion compared equity investment transactions primarily sale elan american depositary shares interest income expense interest income increased million compared due higher average balance cash cash equivalents marketable securities higher interest rates cash cash equivalents marketable securities totaled billion end averaged billion compared billion average cash balance increase yearend cash balance primarily due cash generated operating activities interest expense increased slightly compared average debt balance billion versus billion total debt balance end billion compared billion end higher debt balance approximately billion increase commercial paper general corporate purposes primarily stock repurchase program interest income comparable prior year higher balance cash cash equivalents marketable securities offset lower interest rates cash cash equivalents marketable securities totaled billion end averaged billion compared billion average cash balance increase yearend cash balance primarily due cash generated operating activities interest expense increased million compared due higher average debt balance average debt balance billion versus billion total debt balance end billion compared billion end higher debt balance approximately billion due increased borrowings november company increased borrowings capitalizing favorable terms capital markets proceeds borrowings used general corporate purposes income tax segment income tax segment business follows percent segment sales dollars millions consumer pharmaceutical medical devices total less expenses allocated segments earnings provision taxes income see note consolidated financial statements details amounts allocated segments include interest income expense noncontrolling interests general corporate income expense consumer segment consumer segment income tax percent sales versus primarily due lower divestiture gains versus consumer segment tax included gain billion divestitures primarily divestiture splenda brand consumer segment included gain billion divestitures primarily divestiture ky brand consumer segment income tax percent sales flat prior year pharmaceutical segment pharmaceutical segment income tax percent sales versus favorable income tax primarily due higher gains recognized partially offset sales decline olysiosovriadsimeprevir increased investment spending negative currency impacts compared included gain billion us divestiture nucyntaas well receipt contingent payment positive adjustment previous reserve estimates including managed medicaid rebates additionally pharmaceutical segment income tax negatively impacted billion additional year branded prescription drug fee higher intangible asset amortization expense billion primarily related writedown incivo telaprevir pharmaceutical segment income tax percent sales versus favorable income tax attributable strong sales volume growth particularly sales olysiosovriad simeprevir positive sales mix higher margin products cost containment initiatives realized selling marketing administrative expenses partially offset billion additional year branded prescription drug fee billion intangible asset writedown related incivo telaprevir additionally included net gain billion equity investment transactions primarily sale elan american depositary shares positive adjustment billion previous estimates managed medicaid rebates partially offset higher writedowns billion impairment iprd compared medical devices segment medical devices segment income tax percent sales versus primarily due restructuring charge billion intangible asset writedown billion related acclarent lower gains billion divestitures compared medical devices segment included gains billion primarily divestiture cordis business versus gain billion recorded divestiture orthoclinical diagnostics business income tax favorably impacted lower net litigation expense billion included gain litigation settlement agreement billion guidant lower synthes integration costs billion compared medical devices segment income tax percent sales versus favorable income tax attributable net gain billion divestiture orthoclinical diagnostics business lower litigation expense billion compared restructuring company announced restructuring actions medical devices segment expected result annualized pretax cost savings million billion majority expected realized end including approximately million savings savings provide company added flexibility resources fund investment new growth opportunities innovative solutions customers patients company estimates connection plans record pretax restructuring charges approximately billion billion expected incurred fiscal fourth quarter company recorded pretax charge billion million included cost products sold see note consolidated financial statements additional details related restructuring provision taxes income worldwide effective income tax rate effective tax rate decrease compared primarily attributable increases taxable income lower tax jurisdictions relative higher tax jurisdictions tax benefit resulting restructuring international affiliates additionally effective tax rate affected items mentioned increase effective tax rate compared attributable following divestiture orthoclinical diagnostics business approximate effective tax rate litigation accruals low tax rates mix earnings higher tax jurisdictions primarily us accrual additional year branded prescription drug fee tax deductible additional us tax expense related planned increase dividends current year foreign earnings compared prior year increases effective tax rate partially offset tax benefit billion associated conor medsystems divestiture effective tax rate also reduced company adjusted unrecognized tax benefits result federal appeals courts decision omj pharmaceuticals incs litigation regarding credits former section internal revenue code see note consolidated financial statements additional information ii settlement substantially issues related companys us internal revenue service audit tax years effective tax rate reduced tax benefit associated writeoff assets tax purposes associated scios inc inclusion benefit research development tax credit controlled foreign corporation lookthrough provisions provisions enacted law january retroactive january liquidity capital resources liquidity cash flows cash cash equivalents billion end compared billion end primary sources uses cash contributed billion decrease approximately billion cash generated operating activities offset billion net cash used investing activities billion net cash used financing activities billion due effect exchange rate changes cash cash equivalents addition company billion marketable securities end billion end see note consolidated financial statements additional details cash cash equivalents marketable securities cash flow operations billion result billion net earnings billion noncash charges adjustments depreciation amortization stockbased compensation assets writedowns primarily related acclarent venezuela writedowns reduced billion net gains sale assetsbusinesses billion related deferred taxes accounts receivable inventories additional sources operating cash flow billion resulted decrease current noncurrent assets increase current noncurrent liabilities investing activities use billion primarily net purchases investments marketable securities billion additions property plant equipment billion acquisitions net cash acquired billion partially offset billion proceeds disposal assetsbusinesses financing activities use billion primarily dividends shareholders billion billion repurchase common stock financing activities also included source billion net proceeds short longterm debt billion net proceeds stock options exercised associated tax benefits october company announced board directors approved share repurchase program authorizing company purchase billion company 's shares common stock january billion repurchased program repurchase program time limit may suspended periods discontinued time shares acquired available general corporate purposes company intends finance share repurchase program available cash access capital markets previous share repurchase program approved july authorizing company purchase billion company 's shares ofcommon stock completed april company continued access liquidity commercial paper market company shelf registration us securities exchange commission enables company issue debt securities warrants purchase debt securities timely basis additional details borrowings see note consolidated financial statements company anticipates operating cash flows existing credit facilities access capital markets provide sufficient resources fund operating needs concentration credit risk global concentration credit risk respect trade accounts receivables continues limited due large number customers globally adherence internal credit policies credit limits economic challenges italy spain greece portugal southern european region impacted certain payment patterns historically longer experienced us international markets total net trade accounts receivable balance southern european region approximately billion january billion december approximately billion january approximately billion december southern european region net trade accounts receivable balance related company 's consumer vision care diabetes care businesses well certain pharmaceutical medical devices customers line historical collection patterns remaining balance net trade accounts receivable southern european region negatively impacted timing payments certain government owned supported health care customers well certain distributors pharmaceutical medical devices local affiliates total net trade accounts receivable balance customers approximately billion january billion december company continues receive payments customers cases late payments interest customers payment expected periods time longer one year revenue trade receivables discounted estimated period time collection allowances doubtful accounts increased customers immaterial date company continue work closely customers payment plans monitor economic situation take appropriate actions necessary financing market risk company uses financial instruments manage impact foreign exchange rate changes cash flows accordingly company enters forward foreign exchange contracts protect value certain foreign currency assets liabilities hedge future foreign currency transactions primarily related product costs gains losses contracts offset gains losses underlying transactions appreciation us dollar january market rates would increase unrealized value companys forward contracts million conversely depreciation us dollar january market rates would decrease unrealized value companys forward contracts million either scenario gain loss forward contract would offset gain loss underlying transaction therefore would impact future anticipated earnings cash flows company hedges exposure fluctuations currency exchange rates effect certain assets liabilities foreign currency entering currency swap contracts change spread us foreign interest rates companys interest rate sensitive financial instruments would either increase decrease unrealized value companys swap contracts approximately million either scenario maturity gain loss swap contract would offset gain loss underlying transaction therefore would impact future anticipated cash flows company enter financial instruments trading speculative purposes company policy entering contracts parties least investment grade credit rating counterparties contracts major financial institutions significant concentration exposure one counterparty management believes risk loss remote company invests fixed rate floating rate interest earning securities carry degree interest rate risk fair market value fixed rate securities may adversely impacted due rise interest rates floating rate securities may produce less income predicted interest rates fall basis points change spread companys interest rate sensitive investments would either increase decrease unrealized value cash equivalents current marketable securities approximately million company access substantial sources funds numerous banks worldwide september company secured new day credit facility total credit available company approximates billion expires september interest charged borrowings credit line agreement based either bids provided banks prime rate london interbank offered rates libor plus applicable margins commitment fees agreement material total borrowings end billion billion respectively increase borrowingsbetween result financing company 's share repurchase program net cash cash current marketable securities net debt billion compared net cash billion total debt represented total capital shareholders equity total debt total capital shareholders equity per share end compared yearend increase summary borrowings found note consolidated financial statements contractual obligations commitments companys contractual obligations primarily leases debt unfunded retirement plans significant obligations satisfy obligations company use cash operations following table summarizes companys contractual obligations aggregate maturities january see notes consolidated financial statements details interest unfunded debt debt retirement operating dollars millions obligations obligations plans leases total total tax matters see note consolidated financial statements dividends company increased dividend rd consecutive year cash dividends paid per share compared dividends per share per share dividends distributed follows first quarter second quarter third quarter fourth quarter total january board directors declared regular quarterly cash dividend per share payable march shareholders record february company expects continue practice paying regular cash dividends information critical accounting policies estimates managements discussion analysis results operations financial condition based companys consolidated financial statements prepared accordance accounting principles generally accepted us gaap preparation financial statements requires management make estimates assumptions affect amounts reported revenues expenses assets liabilities related disclosures actual results may may differ estimates company believes understanding certain key accounting policies estimates essential achieving insight companys operating results financial condition key accounting policies include revenue recognition income taxes legal selfinsurance contingencies valuation longlived assets assumptions used determine amounts recorded pensions employee benefit plans accounting stock based awards revenue recognition company recognizes revenue product sales goods shipped delivered title risk loss pass customer provisions certain rebates sales incentives trade promotions coupons product returnsand discounts customers accounted reductions sales period related sales recorded product discounts granted based terms arrangements direct indirect market participants well market conditions including prices charged competitors rebates include medicaid rebate provision estimated based contractual terms historical experience patient outcomes trend analysis projected market conditions various markets served company evaluates market conditions products groups products primarily analysis wholesaler thirdparty sellthrough market research data well internally generated information sales returns estimated recorded based historical sales returns information products exhibit unusual sales return patterns due dating competition marketing matters specifically investigated analyzed part accounting sales return accruals sales returns allowances represent reserve products may returned due expiration destruction field specific areas product recall returns reserve based historical return trends product market percent gross sales accordance companys accounting policies company generally issues credit customers returned goods companys sales returns reserves accounted accordance us gaap guidance revenue recognition right return exists sales returns reserves recorded full sales value sales returns consumer pharmaceutical segments almost exclusively resalable sales returns certain franchises medical devices segment typically resalable material company infrequently exchanges products inventory returned products sales returns reserve total company approximately annual net trade sales fiscal reporting years promotional programs product listing allowances cooperative advertising arrangements recorded year incurred continuing promotional programs include coupons volumebased sales incentive programs redemption cost consumer coupons based historical redemption experience product value volumebased incentive programs based estimated sales volumes incentive period recorded products sold company also earns service revenue copromotion certain products years presented service revenues less total revenues included sales customers arrangements evaluated determine appropriate amounts deferred recorded reduction revenue addition company enters collaboration arrangements contain multiple revenue generating activities amounts due collaborative partners arrangements recognized activity performed delivered based relative fair value upfront fees received part arrangements deferred recognized performance period see note consolidated financial statements additional disclosures collaborations reasonably likely changes assumptions used calculate accruals rebates returns promotions anticipated material effect financial statements company currently discloses impact changes assumptions quarterly annual filing material financial statement impact tables show progression accrued rebates returns promotions reserve doubtful accounts reserve cash discounts segment business fiscal years ended january december consumer segment balance beginning balance dollars millions period accruals paymentscredits end period accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total includes reserve customer rebates million january million december recorded contra asset pharmaceutical segment balance beginning balance dollars millions period accruals paymentscredits end period accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total includes reserve customer rebates million january million december recorded contra asset prior year amount reclassified conform current year presentation medical devices segment balance beginning balance dollars millions period accruals paymentscredits end period accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total includes reserve customer rebates million january million december recorded contra asset income taxes income taxes recorded based amounts refundable payable current year include results difference us gaap accounting tax reporting recorded deferred tax assets liabilities company estimates deferred tax assets liabilities based enacted tax regulations rates future changes tax laws rates may affect recorded deferred tax assets liabilities company unrecognized tax benefits uncertain tax positions company follows us gaap prescribes recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return management believes changes estimates would material effect company 's results operations cash flows financial position january december cumulative amounts undistributed international earnings approximately billion billion respectively january december company 's foreign subsidiaries held balances cash cash equivalents marketable securities amounts billion billion respectively company provided deferred taxes undistributed earnings certain international subsidiaries earnings considered permanently reinvested company intends continue reinvest earnings international operations company decided later date repatriate earnings us company would required provide net tax effects amounts company determine deferred tax liability associated undistributed earnings determination practical see note consolidated financial statements information regarding income taxes legal self insurance contingencies company records accruals various contingencies including legal proceedings product liability claims arise normal course business accruals based managements judgment probability losses applicable actuarially determined estimates company self insurance whollyowned captive insurance company addition accruals self insurance program claims exceed insurance coverage accrued losses probable amounts reasonably estimated additionally company records insurance receivable amounts thirdparty insurers recovery probable appropriate reserves receivables recorded estimated amounts may collected thirdpartyinsurers company follows provisions us gaap recording litigation related contingencies liability recorded loss probable reasonably estimated best estimate loss within range accrued however estimate range better minimum amount accrued see notes consolidated financial statements information regarding product liability legal proceedings longlived intangible assets company assesses changes economic conditions makes assumptions regarding estimated future cash flows evaluating value companys property plant equipment goodwill intangible assets assumptions estimates may change time may may necessary company record impairment charges employee benefit plans company sponsors various retirement pension plans including defined benefit defined contribution termination indemnity plans cover employees worldwide plans based assumptions discount rate expected return plan assets mortality rates expected salary increases health care cost trend rates attrition rates see note consolidated financial statements details rates effect rate change health care cost trend would companys results operations stock based compensation company recognizes compensation expense associated issuance equity instruments employees services based type equity instrument fair value estimated date grant using either blackscholes option valuation model combination blackscholes option valuation model monte carlo valuation model expensed financial statements service period input assumptions used determining fair value expected life expected volatility riskfree rate expected dividend yield performance share units fair market value calculated three component goals date grant fair values sales earnings per share goals performance share unit estimated date grant using fair market value shares time award discounted dividends paid performance share units vesting period fair value relative total shareholder return goal performance share unit estimated date grant using monte carlo valuation model see note consolidated financial statements additional information new accounting pronouncements refer note consolidated financial statements recently adopted accounting pronouncements recently issued accounting pronouncements yet adopted january economic market factors company aware products used environment decade policymakers consumers businesses expressed concerns rising cost health care response concerns company longstanding policy pricing products responsibly period united states weighted average compound annual growth rate companys net price increases health care products prescription overthecounter drugs hospital professional products us consumer price index cpi company operates certain countries economic conditions continue present significant challenges company continues monitor situations take appropriate actions inflation rates continue effect worldwide economies consequently way companies operate company accounted operations venezuela highly inflationary prior threeyear cumulative inflation rate surpassed face increasing costs company strives maintain profit margins cost reduction programs productivity improvements periodic price increases venezuelan government established alternative systems offerings various foreign currency exchanges company primarily utilized official government rate bolivares fuertes one us dollar preparing consolidated financial statements company applied settle outstanding dividend payable one alternative foreign exchange rates result company applied alternative exchange rate translate certain transactions appropriate fourth quarter number companys transactions conducted official rate declined prior quarters result company determined longer likely outstanding net monetary assets would settled official government rate bolivares fuertes one us dollar therefore company recorded charge million revalue net monetary assets venezuela one governments alternative exchange rates simadi impair nonmonetary assets revaluation january companys venezuelan subsidiaries represented less company 's consolidated assets liabilities due continuing uncertain economic conditions venezuela possible additional charges may recorded future additional charges expected material adverse effect companys full year results company continues business greece company closely monitors economic situation january companys greek subsidiaries represented company 's consolidated assets revenues respectively company exposed fluctuations currency exchange rates change value us dollar ascompared foreign currencies company sales income expense would increased decreased translation foreign sales approximately million income million company faces various worldwide health care changes may continue result pricing pressures include health care cost containment government legislation relating sales promotions reimbursement health care products changes behavior spending patterns purchasers health care products services including delaying medical procedures rationing prescription medications reducing frequency physician visits foregoing health care insurance coverage result current global economic downturn may continue impact companys businesses company also operates environment increasingly hostile intellectual property rights firms filed abbreviated new drug applications biosimilar biological product applications fda otherwise challenged coverage andor validity company 's patents seeking market generic biosimilar forms many companys key pharmaceutical products prior expiration applicable patents covering products event company successful defending patent claims challenged resulting lawsuits generic biosimilar versions products issue introduced market resulting potential substantial market share revenue losses products may result noncash impairment charge associated intangible asset also risk one competitors could launch generic biosimilar version product issue following regulatory approval even though one valid patents place information see discussion remicade related cases litigation filers abbreviated new drug applications note consolidated financial statements legal proceedings johnson johnson certain subsidiaries involved various lawsuits claims regarding product liability intellectual property commercial matters governmental investigations legal proceedings arise time time ordinary course business company records accruals loss contingencies associated legal matters probable liability incurred amount loss reasonably estimated company accrued certain litigation matters continues monitor related legal issue adjust accruals new information developments accordance accounting standards codification asc litigation regulatory matters currently disclosed loss probable reasonably possible company unable estimate possible loss range loss beyond amounts already accrued amounts accrued legal contingencies often result complex series judgments future events uncertainties rely heavily estimates assumptions ability make estimates judgments affected various factors including whether damages sought proceedings unsubstantiated indeterminate scientific legal discovery commenced complete proceedings early stages matters present legal uncertainties significant facts dispute numerous parties involved company 's opinion based examination matters experience date discussions counsel ultimate outcome legal proceedings net liabilities accrued company 's balance sheet expected material adverse effect company 's financial position however resolution increase accruals one matters reporting period may material adverse effect company 's results operations cash flows period see note consolidated financial statements information regarding legal proceedings common stock market prices companys common stock listed new york stock exchange symbol jnj february record holders common stock company composite market price ranges johnson johnson common stock high low high low first quarter second quarter third quarter fourth quarter yearend close cautionary factors may affect future results annual report contains forwardlooking statements forwardlooking statements relate strictly historical current facts anticipate results based managements plans subject uncertainty forwardlooking statements may identified use words plans expects anticipates estimates words similar meaning conjunction among things discussions future operations financial performance companys strategy growth product development regulatory approval market position expenditures forwardlooking statements based current expectations future events company guarantee forwardlooking statement accurate although company believes reasonable expectations assumptions investors realize underlying assumptions prove inaccurate known unknown risks uncertainties materialize actual results could vary materially companys expectations projections investors therefore cautioned place undue reliance forwardlooking statements company undertake update forwardlooking statements result new information future events developments risks uncertainties include limited economic factors interest rate currency exchange rate fluctuations competition including technological advances new products patents attained competitors challenges uncertainties inherent new product development including uncertainty clinical success obtaining regulatory approvals uncertainty commercial success new existing products challenges patents impact patent expirations ability company successfully execute strategic plans including restructuring plans potential expected benefits opportunities related restructuring may realized may take longer realize expected significant adverse litigation government action including related product liability claims impact business combinations divestitures market conditions possibility ongoing share repurchase program may suspended discontinued significant changes customer relationships changes behavior spending patterns financial distress purchasers health care products services changes applicable laws regulations including global health care reforms trends toward health care cost containment increased scrutiny health care industry government agencies financial instability international economies legal systems sovereign risk manufacturing difficulties delays internally within supply chain complex global supply chains increasing regulatory requirements product efficacy safety concerns resulting product recalls regulatory action disruptions due natural disasters potential failure meet obligations compliance agreements government bodies discussion factors could cause actual results differ materially expectations found report fiscal year ended january including exhibit company notes factors permitted private securities litigation reform act item quantitative qualitative disclosures market risk information called item incorporated herein reference item managements discussion analysis results operations financial condition liquidity capital resources financing market risk report note summary significant accounting policies financial instruments notes consolidated financial statements included item report item financial statements supplementary data index audited consolidated financial statements consolidated balance sheets consolidated statements earnings consolidated statements comprehensive income consolidated statements equity consolidated statements cash flows notes consolidated financial statements report independent registered public accounting firm managements report internal control financial reporting johnson johnson subsidiaries consolidated balance sheets january december dollars millions except share per share amounts note assets current assets cash cash equivalents notes marketable securities notes accounts receivable trade less allowances doubtful accounts inventories notes prepaid expenses receivables total current assets property plant equipment net notes intangible assets net notes goodwill notes deferred taxes income note assets total assets liabilities shareholders equity current liabilities loans notes payable note accounts payable accrued liabilities accrued rebates returns promotions accrued compensation employee related obligations accrued taxes income note total current liabilities longterm debt note deferred taxes income note employee related obligations notes liabilities total liabilities shareholders equity preferred stock without par value authorized unissued shares common stock par value per share note authorized shares issued shares accumulated comprehensive income note retained earnings less common stock held treasury cost note shares shares total shareholders equity total liabilities shareholders equity see notes consolidated financial statements johnson johnson subsidiaries consolidated statements earnings dollars shares millions except per share amounts note sales customers cost products sold gross profit selling marketing administrative expenses research development expense inprocess research development interest income interest expense net portion capitalized note income expense net restructuring note earnings provision taxes income provision taxes income note net earnings net earnings per share notes basic diluted cash dividends per share average shares outstanding notes basic diluted see notes consolidated financial statements johnson johnson subsidiaries consolidated statements comprehensive income dollars millions note net earnings comprehensive income loss net tax foreign currency translation securities unrealized holding gain loss arising period reclassifications earnings net change employee benefit plans prior service cost amortization period prior service credit cost current year gain amortization period gain loss current year effect exchange rates net change derivatives hedges unrealized gain loss arising period reclassifications earnings net change comprehensive income loss comprehensive income tax effects comprehensive income fiscal years ended respectively securities million million million employee benefit plans million million million derivatives hedges million million million see notes consolidated financial statements johnson johnson subsidiaries consolidated statements equity dollars millions note accumulated common stock treasury retained comprehensive issued stock total earnings income amount amount balance december net earnings cash dividends paid employee compensation stock option plans repurchase common stock comprehensive income loss net tax balance december net earnings cash dividends paid employee compensation stock option plans repurchase common stock comprehensive income loss net tax balance december net earnings cash dividends paid employee compensation stock option plans repurchase common stock comprehensive income loss net tax balance january see notes consolidated financial statements johnson johnson subsidiaries consolidated statements cash flows dollars millions note cash flows operating activities net earnings adjustments reconcile net earnings cash flows operating activities depreciation amortization property intangibles stock based compensation venezuela adjustments asset writedowns net gain sale assetsbusinesses net gain equity investment transactions deferred tax provision accounts receivable allowances changes assets liabilities net effects acquisitions divestitures increase accounts receivable increase inventories decreaseincrease accounts payable accrued liabilities decreaseincrease current noncurrent assets increasedecrease current noncurrent liabilities net cash flows operating activities cash flows investing activities additions property plant equipment proceeds disposal assetsbusinesses net acquisitions net cash acquired note purchases investments sales investments primarily intangibles net cash used investing activities cash flows financing activities dividends shareholders repurchase common stock proceeds shortterm debt retirement shortterm debt proceeds longterm debt retirement longterm debt proceeds exercise stock optionsexcess tax benefits net cash used financing activities effect exchange rate changes cash cash equivalents decreaseincrease cash cash equivalents cash cash equivalents beginning year note cash cash equivalents end year note supplemental cash flow data cash paid year interest interest net amount capitalized income taxes supplemental schedule noncash investing financing activities treasury stock issued employee compensation stock option plans net cash proceeds conversion debt acquisitions fair value assets acquired fair value liabilities assumed noncontrolling interests net cash paid acquisitions see notes consolidated financial statements notes consolidated financial statements summary significant accounting policies principles consolidation consolidated financial statements include accounts johnson johnson subsidiaries company intercompany accounts transactions eliminated description company business segments company approximately employees worldwide engaged research development manufacture sale broad range products health care field company conducts business virtually countries world primary focus products related human health wellbeing company organized three business segments consumer pharmaceutical medical devices consumer segment includes broad range products used baby care oral care skin care overthecounter pharmaceutical womens health wound care markets products marketed general public sold retail outlets distributors throughout world pharmaceutical segment focused five therapeutic areas including immunology infectious diseases neuroscience oncology cardiovascular metabolic diseases products segment distributed directly retailers wholesalers hospitals health care professionals prescription use medical devices segment includes broad range products used orthopaedic surgery cardiovascular diabetes care vision care fields distributed wholesalers hospitals retailers used principally professional fields physicians nurses hospitals eye care professionals clinics new accounting pronouncements recently adopted accounting pronouncements fiscal second quarter financial accounting standards board fasb issued accounting standard update practical expedient measurement date employers defined benefit obligation plan assets update provides practical expedient option entities defined benefit plans fiscal yearend coincide calendar monthend option allows entity elect measure defined benefit plan assets obligations using calendar monthend closest fiscal yearend update effective company annual interim periods beginning december practical expedient elected entity required adopted prospective basis early adoption permitted company elected adopt practical expedient measure defined benefit plans election material impact companys consolidated financial statements fiscal fourth quarter fasb issued accounting standard update income taxes balance sheet classification deferred taxes simplify presentation deferred income taxes amendments update require deferred tax liabilities assets classified noncurrent classified statement financial position update required effective public companies annual periods beginning december interim periods within annual periods earlier application permitted company elected early adopt standard retrospective basis consolidated balance sheet reclassification reduced current assets billion increased noncurrent assets billion reduced liabilities billion recently issued accounting standards adopted january fiscal first quarter fasb issued accounting standard update recognition measurement financial assets financial liabilities amendments update supersede guidance classify equity securities readily determinable fair values different categories trading availableforsale require equity securities measured fair value changes fair value recognized net income standard amends financial reporting providing relevant information entitys equity investments reducing number items recognized comprehensive income update effective company annual periods beginning december interim periods within annual periods company currently assessing impact future adoption standard financial statements fiscal second quarter fasb issued accounting standard update simplifying presentation debt issuance costs update requires capitalized debt issuance costs presented reduction carrying value debt instead classified deferred charge currently required update effective company forall annual interim periods beginning december required applied retroactively periods presented update material impact presentation companys financial position fiscal second quarter fasb issued accounting standard update simplifying measurement inventory update requires inventory measured lower cost net realizable value net realizable value estimated selling prices ordinary course business less reasonably predictable costs completion disposal transportation update effective company annual interim periods beginning december amendments update applied prospectively earlier application permitted beginning interim annual reporting period update material impact presentation companys financial position fiscal third quarter fasb issued accounting standard update business combinations simplifying accounting measurementperiod adjustments amendments update require acquirer recognize adjustments provisional amounts identified measurement period reporting period adjustment amounts determined update effective company annual interim periods beginning december amendments update applied prospectively adjustments provisional amounts occur effective date update earlier application permitted financial statements issued update expected material impact companys consolidated financial statements fiscal second quarter fasb issued accounting standards update revenue contracts customers standard replaces substantially current revenue recognition accounting guidance fiscal third quarter fasb approved one year deferral effective date adopted public companies annual periods interim reporting periods beginning december early adoption standard permitted original effective date annual periods interim reporting periods beginning december company currently assessing impact future adoption standard financial statements fiscal second quarter fasb issued amended guidance accounting standards update development stage entities elimination certain financial reporting requirements including amendment variable interest entity guidance topic consolidation change current guidance require company determine consolidate one entities based change consolidation analysis update consolidation analysis become effective annual periods interim reporting periods beginning december adoption standard expected material impact presentation company 's consolidated financial statements fiscal third quarter fasb issued accounting standards update disclosure uncertainties entitys ability continue going concern standard requires management evaluate annual interim reporting period whether conditions events considered aggregate raise substantial doubt entitys ability continue going concern within one year date financial statements issued available issued substantial doubt raised additional disclosures around managements plan alleviate doubts required update become effective annual periods interim reporting periods ending december standard expected impact current disclosures financial statements cash equivalents company classifies highly liquid investments stated maturities three months less date purchase cash equivalents highly liquid investments stated maturities greater three months date purchase current marketable securities company policy making investments commercial institutions least investment grade credit rating company invests cash primarily reverse repurchase agreements rras government securities obligations corporate debt securities money market funds rras collateralized deposits form government securities obligations amount less value company record asset liability company permitted sell repledge associated collateral company policy collateral least equivalent credit rating company utilizes third party custodian manage exchange funds ensure collateral received maintained value rras daily basis rras stated maturities greater three months date purchase classified marketable securitiesinvestments investments classified held maturity investments reported amortized cost realized gains losses reported earnings investments classified availableforsale carried estimated fair value unrealized gains losses recorded component accumulated comprehensive income availableforsale securities available current operations classified current assets management determines appropriate classification investment debt equity securities time purchase reevaluates determination balance sheet date company periodically reviews investments equity securities impairment adjusts investments fair value decline market value deemed temporary losses securities considered temporary loss recognized earnings property plant equipment depreciation property plant equipment stated cost company utilizes straightline method depreciation estimated useful lives assets building building equipment years land leasehold improvements years machinery equipment years company capitalizes certain computer software development costs included machinery equipment incurred connection developing obtaining computer software internal use capitalized software costs amortized estimated useful lives software generally range years company reviews longlived assets assess recoverability using undiscounted cash flows certain events changes operating economic conditions occur impairment assessment may performed recoverability carrying value assets asset determined impaired loss measured based difference assets fair value carrying value quoted market prices available company estimate fair value using discounted value estimated future cash flows revenue recognition company recognizes revenue product sales goods shipped delivered title risk loss pass customer provisions certain rebates sales incentives trade promotions coupons product returns discounts customers accounted reductions sales period related sales recorded product discounts granted based terms arrangements direct indirect market participants well market conditions including prices charged competitors rebates include medicaid estimated based contractual terms historical experience patient outcomes trend analysis projected market conditions various markets served company evaluates market conditions products groups products primarily analysis wholesaler thirdparty sellthrough market research data well internally generated information sales returns generally estimated recorded based historical sales returns information products exhibit unusual sales return patterns due dating competition marketing matters specifically investigated analyzed part accounting sales returns accruals sales returns allowances represent reserve products may returned due expiration destruction field specific areas product recall returns reserve based historical return trends product market percent gross sales accordance companys accounting policies company generally issues credit customers returned goods companys sales returns reserves accounted accordance us gaap guidance revenue recognition right return exists sales returns reserves recorded full sales value sales returns consumer pharmaceutical segments almost exclusively resalable sales returns certain franchises medical devices segment typically resalable material company infrequently exchanges products inventory returned products sales returns reserve total company approximately annual sales customers fiscal reporting years promotional programs product listing allowances cooperative advertising arrangements recorded year incurred continuing promotional programs include coupons volumebased sales incentive programs redemption cost consumer coupons based historical redemption experience product value volumebased incentive programs based estimated sales volumes incentive period recorded products sold company also earns service revenue copromotion certain products includes sales customers arrangements evaluated determine appropriate amounts deferred recorded reduction revenueshipping handling shipping handling costs incurred million million million respectively included selling marketing administrative expense amount revenue received shipping handling less sales customers periods presented inventories inventories stated lower cost market determined firstin firstout method intangible assets goodwill authoritative literature us gaap requires goodwill intangible assets indefinite lives assessed annually impairment company completed annual impairment test fiscal fourth quarter future impairment tests performed annually fiscal fourth quarter sooner warranted purchased inprocess research development accounted indefinite lived intangible asset underlying project completed point intangible asset accounted definite lived intangible asset abandoned point intangible asset written partially impaired intangible assets finite useful lives continue amortized useful lives reviewed impairment warranted economic conditions see note details intangible assets goodwill financial instruments required us gaap derivative instruments recorded balance sheet fair value fair value exit price would received sell asset paid transfer liability fair value marketbased measurement determined using assumptions market participants would use pricing asset liability authoritative literature establishes threelevel hierarchy prioritize inputs used measuring fair value level highest priority level lowest changes fair value derivatives recorded period current earnings comprehensive income depending whether derivative designated part hedge transaction type hedge transaction company documents relationships hedged items derivatives overall risk management strategy includes reasons undertaking hedge transactions entering derivatives objectives strategy minimize foreign currency exposures impact companys financial performance protect companys cash flow adverse movements foreign exchange rates ensure appropriateness financial instruments manage enterprise risk associated financial institutions see note additional information financial instruments product liability accruals product liability claims recorded undiscounted basis probable liability incurred amount liability reasonably estimated based existing information actuarially determined estimates applicable accruals adjusted periodically additional information becomes available company accrues estimate legal defense costs needed defend matter costs probable reasonably estimated result cost availability factors effective november company ceased purchasing thirdparty product liability insurance company self insurance whollyowned captive insurance company addition accruals self insurance program claims exceed insurance coverage accrued losses probable amounts reasonably estimated based availability prior coverage receivables insurance recoveries related product liability claims recorded undiscounted basis probable recovery realized appropriate reserves receivables recorded estimated amounts may collected thirdparty insurers concentration credit risk global concentration credit risk respect trade accounts receivables continues limited due large number customers globally adherence internal credit policies credit limits economic challenges italy spain greece portugal southern european region impacted certain payment patterns historically longer experienced us international markets total net trade accounts receivable balance southern european region approximately billion january approximately billion december approximately billion january approximately billion december southern european region net trade accounts receivable balance related company 's consumer vision care diabetes care businesses well certain pharmaceutical medical devices customers line historical collection patterns remaining balance net trade accounts receivable southern european region negatively impacted timing payments certain government owned supported health care customers well certain distributors pharmaceutical medical devices local affiliates total net trade accounts receivable balance customerswere approximately billion january billion december company continues receive payments customers cases late payments interest customers payment expected periods time longer one year revenue trade receivables discounted estimated period time collection allowances doubtful accounts increased customers immaterial date company continue work closely customers payment plans monitor economic situation take appropriate actions necessary research development research development expenses expensed incurred upfront milestone payments made third parties connection research development collaborations expensed incurred point regulatory approval payments made third parties subsequent regulatory approval capitalized amortized remaining useful life related product amounts capitalized payments included intangibles net accumulated amortization company enters collaborative arrangements typically pharmaceutical biotechnology companies develop commercialize drug candidates intellectual property arrangements typically involve two parties active participants collaboration exposed significant risks rewards dependent commercial success activities collaborations usually involve various activities one parties including research development marketing selling distribution often collaborations require upfront milestone royalty profit share payments contingent upon occurrence certain future events linked success asset development amounts due collaborative partners related development activities generally reflected reduction research development expense performance contract development services central companys operations general income statement presentation collaborations follows naturetype collaboration statement earnings presentation thirdparty sale product sales customers royaltiesmilestones paid collaborative partner post cost products sold regulatory approval royalties received collaborative partner income expense net upfront payments milestones paid collaborative partner research development expense preregulatory approval research development payments collaborative partner research development expense research development payments received reduction research development expense collaborative partner milestones capitalized intangible assets amortized cost goods sold useful life years presented individual project represented greater total annual consolidated research development expense company number products compounds developed collaboration strategic partners including xarelto codeveloped bayer healthcare ag imbruvica developed collaboration comarketed pharmacyclics llc abbvie company advertising costs associated advertising expensed year incurred included selling marketing administrative expenses advertising expenses worldwide comprised television radio print media internet advertising billion billion billion respectively income taxes income taxes recorded based amounts refundable payable current year include results difference us gaap accounting tax reporting recorded deferred tax assets liabilities company estimates deferred tax assets liabilities based enacted tax regulations rates future changes tax laws rates may affect recorded deferred tax assets liabilities future company unrecognized tax benefits uncertain tax positions company follows us gaap prescribes recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return management believes changes estimates would material effect company 's results operations cash flows financial position january december cumulative amounts undistributed international earnings approximately billion billion respectively january december company 's foreign subsidiaries held balances cash cash equivalents marketable securities amounts billion billion respectively company provided deferred taxes undistributed earnings certain international subsidiaries earnings considered permanently reinvested company intends continue reinvest earnings international operations company decided later date repatriate earnings us company would required provide net tax effects amounts company determine deferred tax liability associated undistributed earnings determination practical see note consolidated financial statements information regarding income taxes net earnings per share basic earnings per share computed dividing net earnings available common shareholders weighted average number common shares outstanding period diluted earnings per share reflects potential dilution could occur securities exercised converted common stock using treasury stock method use estimates preparation consolidated financial statements conformity accounting principles generally accepted us requires management make estimates assumptions affect amounts reported estimates used accounting sales discounts rebates allowances incentives product liabilities income taxes depreciation amortization employee benefits contingencies intangible asset liability valuations actual results may may differ estimates company follows provisions us gaap recording litigation related contingencies liability recorded loss probable reasonably estimated best estimate loss within range accrued however estimate range better minimum amount accrued annual closing date company follows concept fiscal year ends sunday nearest end month december normally fiscal year consists weeks every five six years fiscal year consists weeks case case reclassification certain prior period amounts reclassified conform current year presentation cash cash equivalents current marketable securities end cash cash equivalents current marketable securities comprised dollars millions current carrying unrecognized unrecognized estimated cash marketable amount gain loss fair value equivalents securities cash us gov't securities sovereign securities us reverse repurchase agreements reverse repurchase agreements corporate debt securities money market funds time deposits carrying unrealized estimated amount gain unrealized loss fair value gov't securities corporate debt securities available sale total cash cash equivalents current marketable securities dollars millions current carrying unrecognized unrecognized estimated cash marketable amount gain loss fair value equivalents securities cash us gov't securities sovereign securities us reverse repurchase agreements reverse repurchase agreements corporate debt securities money market funds time deposits total cash cash equivalents current marketable securities held maturity investments reported amortized cost realized gains losses reported earnings available sale securities reported fair value unrealized gains losses reported net taxes comprehensive income fair value government securities obligations corporate debt securities estimated using quoted broker prices significant observable inputs contractual maturities substantially available sale securities one five years january company invests excess cash deposits major banks throughout world highquality money market instruments company policy making investments commercial institutions least investment grade credit rating inventories end inventories comprised dollars millions raw materials supplies goods process finished goods total inventories property plant equipment end property plant equipment cost accumulated depreciation dollars millions land land improvements buildings building equipment machinery equipment construction progress total property plant equipment gross less accumulated depreciation total property plant equipment net company capitalizes interest expense part cost construction facilities equipment interest expense capitalized million million million respectively depreciation expense including amortization capitalized interest billion billion billion respectively upon retirement disposal property plant equipment costs related amounts accumulated depreciation amortization eliminated asset accumulated depreciation accounts respectively difference net asset value proceeds recorded earnings intangible assets goodwill end gross net amounts intangible assets dollars millions intangible assets definite lives patents trademarks gross less accumulated amortization patents trademarks net customer relationships intangibles gross less accumulated amortization customer relationships intangibles net intangible assets indefinite lives trademarks purchased inprocess research development total intangible assets indefinite lives total intangible assets net goodwill january december allocated segment business follows dollars millions consumer pharmaceutical med devices total goodwill december goodwill related acquisitions goodwill related divestitures currency translationother goodwill december goodwill related acquisitions goodwill related divestitures currency translationother goodwill january weighted average amortization periods patents trademarks customer relationships intangible assets years years respectively amortization expense amortizable assets included cost products sold billion billion billion tax fiscal years ended january december december respectively estimated amortization expense five succeeding years approximates billion tax per year intangible asset writedowns included income expense net see note consolidated financial statements additional details related acquisitions divestitures fair value measurements company uses forward foreign exchange contracts manage exposure variability cash flows primarily related foreign exchange rate changes future intercompany products thirdparty purchases materials denominated foreign currency company uses cross currency interest rate swaps manage currency risk primarily related borrowings types derivatives designated cash flow hedges additionally company uses interest rate swaps instrument manage interest rate risk related fixed rate borrowings derivatives treated fair value hedges company may use forward foreign exchange contracts designated net investment hedges additionally company uses forward foreign exchange contracts offset exposure certain foreign currency assets liabilities forward foreign exchange contracts designated hedges therefore changes fair values derivatives recognized earnings thereby offsetting current earnings effect related foreign currency assets liabilities company enter derivative financial instruments trading speculative purposes contain credit risk related contingent features requirements post collateral either company counterparty ongoing basis company monitors counterparty credit ratings company considers credit nonperformance risk low company primarily enters agreements commercial institutions least investment grade credit rating refer table significant financial assets liabilities measured fair value contained footnote receivables payables commercial institutions january company notional amounts outstanding forward foreign exchange contracts cross currency interest rate swaps interest rate swaps billion billion billion respectively derivative instruments recorded balance sheet fair value changes fair value derivatives recorded period current earnings comprehensive income depending whether derivative designated part hedge transaction type hedge transaction designation cash flow hedge made entrance date derivative contract inception derivatives expected highly effective changes fair value derivative designated cash flow hedge highly effective recorded accumulated comprehensive income underlying transaction affects earnings reclassified earnings account hedged transaction gains losses associated interest rate swaps changes fair value hedged debt attributable changes interest rates recorded interest expense period occur gains losses net investment hedges accounted currency translation account insignificant ongoing basis company assesses whether derivative continues highly effective offsetting changes hedged items derivative longer expected highly effective hedge accounting discontinued hedge ineffectiveness included current period earnings income expense net forward foreign exchange contracts cross currency interest rate swaps interest rate swaps designated fair valuehedges hedge ineffectiveness included current period earnings within interest expense current reporting period hedge ineffectiveness associated interest rate swaps material january balance deferred net losses derivatives included accumulated comprehensive income million aftertax additional information see consolidated statements comprehensive income note company expects substantially amounts related forward foreign exchange contracts reclassified earnings next months result transactions expected occur period maximum length time company hedging transaction exposure months excluding interest rate contracts amount ultimately realized earnings may differ foreign exchange rates change realized gains losses ultimately determined actual exchange rates maturity derivative following table summary activity related derivatives designated cash flow hedges fiscal years ended january december gainloss reclassified gainloss recognized accumulated oci gainloss recognized dollars millions accumulated oci income incomeexpense cash flow hedges income statement caption sales customers cost products sold research development expense interest incomeinterest expense net income expense net total amounts shown table net tax effective portion ineffective portion forward foreign exchange contracts cross currency interest rate swaps fiscal years ended january december loss million gain million respectively recognized income expense net relating forward foreign exchange contracts designated hedging instruments fair value exit price would received sell asset paid transfer liability fair value marketbased measurement determined using assumptions market participants would use pricing asset liability authoritative literature establishes threelevel hierarchy prioritize inputs used measuring fair value levels within hierarchy described level highest priority level lowest fair value derivative financial instrument ie forward foreign exchange contracts interest rate contracts aggregation currency future cash flows discounted present value prevailing market interest rates subsequently converted us dollar current spot foreign exchange rate company believe fair values derivative instruments materially differ amounts could realized upon settlement maturity changes fair value material effect companys results operations cash flows financial position company also holds equity investments classified level debt securities classified level company significant financial assets liabilities would require revised valuations standard recognized fair value following three levels inputs used measure fair value level quoted prices active markets identical assets liabilities level significant observable inputs level significant unobservable inputs companys significant financial assets liabilities measured fair value january december follows dollars millions level level level total total derivatives designated hedging instruments assets forward foreign exchange contracts interest rate contracts total liabilities forward foreign exchange contracts interest rate contracts total derivatives designated hedging instruments assets forward foreign exchange contracts liabilities forward foreign exchange contracts available sale investments equity investments debt securities assets liabilities classified level exception equity investments million classified level includes million million noncurrent assets fiscal years ending january december respectively includes million million noncurrent liabilities fiscal years ending january december respectively includes cross currency interest rate swaps interest rate swaps classified noncurrent assets carrying amount equity investments million million january december respectively unrealized gains million million january december respectively unrealized losses million million january december respectively classified current marketable securities classified current assets classified accounts payable see notes financial assets liabilities held carrying amount consolidated balance sheet borrowings components longterm debt follows effective effective rate rate dollars millions notes due month libor frn due notes due debentures due notes due debentures due notes due notes due b euro b euro notes due zero coupon convertible subordinated debentures due debentures due notes due notes due debentures due notes due notes due mm gbp mm gbp notes due debentures due notes due notes due debentures due debentures due notes due notes due subtotal less current portion total longterm debt weighted average effective rate translation rate january translation rate december excess fair value carrying value debt billion billion fair value noncurrent debt estimated using market prices corroborated quoted broker prices significant observable inputs company access substantial sources funds numerous banks worldwide september company secured new day credit facility total credit available company approximates billion expires onseptember interest charged borrowings credit line agreements based either bids provided banks prime rate london interbank offered rates libor plus applicable margins commitment fees agreements material throughout company continued access liquidity commercial paper market shortterm borrowings current portion longterm debt amounted approximately billion end billion borrowed commercial paper program remainder principally represents local borrowing international subsidiaries aggregate maturities longterm obligations commencing dollars millions income taxes provision taxes income consists dollars millions currently payable us taxes international taxes total currently payable deferred us taxes international taxes total deferred provision taxes income comparison income tax expense us statutory rate companys effective tax rate follows dollars millions us international earnings taxes income tax rates us statutory rate international operations excluding ireland ireland puerto rico operations research orphan drug tax credits us state local us manufacturing deduction us tax international income us tax benefit assetbusiness disposals effective tax rate company subsidiaries operating puerto rico various tax incentives effective tax rate decrease compared primarily attributable increases taxable income lower tax jurisdictions relative higher tax jurisdictions tax benefit resulting restructuring international affiliates additionally effective tax rate affected items mentioned belowthe increase effective tax rate compared attributable following divestiture ortho clinical diagnostics business approximate effective tax rate litigation accruals low tax rates mix earnings higher tax jurisdictions primarily us accrual additional year branded prescription drug fee tax deductible additional us tax expense related planned increase dividends current year foreign earnings compared prior year increases effective tax rate partially offset tax benefit billion associated conor medsystems divestiture effective tax rate reduced tax benefit associated writeoff assets tax purposes associated scios inc inclusion benefit research development tax credit controlled foreign corporation lookthrough provisions provisions enacted law january retroactive january effective tax rate also reduced company adjusted unrecognized tax benefits result federal appeals courts decision omj pharmaceuticals incs litigation regarding credits former section internal revenue code see note consolidated financial statements additional information ii settlement substantially issues related companys us internal revenue service audit tax years impact settlement reflected us tax international income line items within reconciliation items noted reflect key drivers rate reconciliation temporary differences carryforwards follows deferred tax deferred tax dollars millions asset liability asset liability employee related obligations stock based compensation depreciation nondeductible intangibles international rd capitalized tax reserves liabilities income reported tax purposes net operating loss carryforward international miscellaneous international miscellaneous us total deferred income taxes million net valuation allowance related belgium million million net valuation allowance related belgium million company whollyowned international subsidiaries cumulative net losses company believes likely subsidiaries realize future taxable income sufficient utilize deferred tax assets following table summarizes activity related unrecognized tax benefits dollars millions beginning year increases related current year tax positions increases related prior period tax positions decreases related prior period tax positions settlements lapse statute limitations end year unrecognized tax benefits billion january recognized would affect companys annual effective tax rate company conducts business files tax returns numerous countries currently tax audits progress number tax authorities irs completed audit tax years currently auditing tax years major jurisdictions company conducts business years remain open generally back year company believes possible audits may completed tax authorities jurisdictions next twelve months however company able provide reasonably reliable estimate timing future tax payments relating uncertain tax positions company classifies liabilities unrecognized tax benefits related interest penalties longterm liabilitiesinterest expense penalties related unrecognized tax benefits classified income tax expense company recognized tax interest expense million million million respectively total amount accrued interest million million respectively employee related obligations end employee related obligations recorded consolidated balance sheets dollars millions pension benefits postretirement benefits postemployment benefits deferred compensation total employee obligations less current benefits payable employee related obligations noncurrent prepaid employee related obligations million million respectively included assets consolidated balance sheets pensions benefit plans company sponsors various retirement pension plans including defined benefit defined contribution termination indemnity plans cover employees worldwide company also provides postretirement benefits primarily health care eligible us retired employees dependents many international employees covered governmentsponsored programs cost company significant retirement plan benefits employees hired january primarily based employees compensation last three five years retirement number years service company announced us defined benefit plan amended adopt new benefit formula effective employees hired january benefits calculated using new formula based employee compensation total years service international subsidiaries plans funds deposited trustees annuities purchased group contracts reserves provided company fund retiree health care benefits advance right modify plans future described note consolidated financial statements company elected early adopt practical expedient beginning fiscal year end measure defined benefit plans using calendar month end closest fiscal year end company used december december respectively measurement date us international retirement benefit plans net periodic benefit costs companys defined benefit retirement plans benefit plans include following components retirement plans benefit plans dollars millions service cost interest cost expected return plan assets amortization prior service cost credit amortization net transition obligation recognized actuarial losses curtailments settlements net periodic benefit cost amounts expected recognized net periodic benefit cost coming year companys defined benefit retirement plans postretirement plans dollars millions amortization net transition obligation amortization net actuarial losses amortization prior service credit unrecognized gains losses us pension plans amortized average remaining future service plan plans active employees amortized average life expectancy amortization gains losses us benefit plans determined using corridor greater market value assets accumulated postretirement benefit obligation total unamortized gains losses excess corridor amortized average remaining future service prior service costsbenefits us pension plans amortized average remaining future service plan participants time plan amendment prior service costbenefit us benefit plans amortized average remaining service full eligibility age plan participants time plan amendment following table represents weightedaverage actuarial assumptions retirement plans benefit plans worldwide benefit plans net periodic benefit cost discount rate rate increase compensation levels expected longterm rate return plan assets benefit obligation discount rate rate increase compensation levels companys discount rates determined considering current yield curves representing high quality longterm fixed income instruments resulting discount rates consistent duration plan liabilities fiscal year company change methodology determining service interest cost single weighted average discount rate approach duration specific spot rates along yield curve plans liability cash flows management concluded precise estimate prior change methodology company measured service interest costs utilizing single weightedaverage discount rate derived yield curve used measure plan obligations company accounted change change accounting estimate accordingly accounted prospective basis change impact benefit obligation material impact full year results expected rates return plan asset assumptions represent company 's assessment longterm returns diversified investment portfolios globally assessment determined using projections external financial sources longterm historical averages actual returns asset class various asset class allocations market measurement us retirement benefit obligations mortality assumption updated newly established mortality table resulting increase projected benefit obligationthe following table displays assumed health care cost trend rates individuals health care plans health care cost trend rate assumed next year rate cost trend rate assumed decline ultimate trend year rate reaches ultimate trend rate onepercentagepoint change assumed health care cost trend rates would following effect onepercentage onepercentage dollars millions point increase point decrease health care plans total interest service cost postretirement benefit obligation following table sets forth information related benefit obligation fair value plan assets yearend companys defined benefit retirement plans postretirement plans retirement plans benefit plans dollars millions change benefit obligation projected benefit obligation beginning year service cost interest cost plan participant contributions amendments actuarial gains losses divestitures acquisitions curtailments settlements restructuring benefits paid plan effect exchange rates projected benefit obligation end year change plan assets plan assets fair value beginning year actual return plan assets company contributions plan participant contributions settlements divestitures acquisitions benefits paid plan assets effect exchange rates plan assets fair value end year funded status end year amounts recognized companys balance sheet consist following noncurrent assets current liabilities noncurrent liabilities total recognized consolidated balance sheet end year amounts recognized accumulated comprehensive income consist following net actuarial loss prior service cost credit unrecognized net transition obligation total tax effects accumulated benefit obligations end year retirement plans benefit plans dollars millions amounts recognized net periodic benefit cost comprehensive income net periodic benefit cost net actuarial gain loss amortization net actuarial loss prior service cost credit amortization prior service cost credit effect exchange rates total recognized comprehensive income tax total recognized net periodic benefit cost comprehensive income company plans continue fund us qualified plans comply pension protection act international plans funded accordance local regulations additional discretionary contributions made deemed appropriate meet longterm obligations plans certain plans funding common practice funding provides economic benefit consequently company several pension plans funded company contributed million million us international pension plans respectively following table displays funded status company 's us qualified nonqualified pension plans international funded unfunded pension plans december december respectively us plans international plans qualified plans nonqualified plans funded plans unfunded plans dollars millions plan assets projected benefit obligation accumulated benefit obligation funded status projected benefit obligation accumulated benefit obligation plans accumulated benefit obligations excess plan assets accumulated benefit obligation projected benefit obligation plan assets billion billion billion respectively end billion billion billion respectively end following table displays projected future benefit payments companys retirement benefit plans dollars millions projected future benefit payments retirement plans benefit plans following table displays projected future minimum contributions unfunded retirement plans amounts include discretionary contributions company may elect make future dollars millions projected future contributions pension plan overseen local committee board responsible overall administration investment pension plans determining investment policies strategies goals committee board considers factors including local pension rules regulations local tax regulations availability investment vehicles separate accounts commingled accounts insurance funds etc funded status plans ratio actives retirees duration liabilities relevant factors including diversification liquidity local markets liquidity base currency majority companys pension funds open new entrants expected ongoing plans permitted investments primarily liquid andor listed little reliance illiquid nontraditional investments hedge funds companys retirement plan asset allocation end target allocations follows percent target plan assets allocation worldwide retirement plans equity securities debt securities total plan assets determination fair value plan assets plan established welldocumented process determining fair values fair value based upon quoted market prices available listed prices quotes available fair value based upon models primarily use inputs marketbased independently sourced market parameters including yield curves interest rates volatilities equity debt prices foreign exchange rates credit curves plan believes valuation methods appropriate consistent market participants use different methodologies assumptions determine fair value certain financial instruments could result different estimate fair value reporting date valuation hierarchy authoritative literature establishes threelevel hierarchy prioritize inputs used measuring fair value levels within hierarchy described table level highest priority level lowest financial instruments categorization within valuation hierarchy based upon lowest level input significant fair value measurement following description valuation methodologies used investments measured fair value shortterm investments cash quoted shortterm instruments valued closing price amount held deposit custodian bank investments investment vehicles valued using net asset value nav provided administrator fund nav based value underlying assets owned fund minus liabilities divided number shares outstanding nav quoted price market active classified level government agency securities limited number investments valued closing price reported major market individual securities traded quoted prices available active market investments classified within level valuation hierarchy quoted market prices available specific security fair values estimated using pricing models quoted prices securities similar characteristics discounted cash flows quoted market prices security available active market classified level debt instruments limited number investments valued closing price reported major market individual securities traded quoted prices available active market investments classified level quoted market prices available specific security fair values estimated using pricing models quoted prices securities similar characteristics discounted cash flows classified level level debt instruments priced based unobservable inputs equity securities common stocks valued closing price reported major market individual securities traded substantially common stock classified within level valuation hierarchy commingled funds investment vehicles valued using nav provided fund administrator nav based value underlying assets owned fund minus liabilities divided number shares outstanding assets level category quoted market price market active insurance contracts instruments issued insurance companies fair value based negotiated value underlying investments held separate account portfolios well considering credit worthiness issuer underlying investments government assetbacked fixed income securities general insurance contracts classified level quoted prices observable inputs pricing assets assets represented primarily limited partnerships real estate investments well commercial loans commercial mortgages classified corporate debt assets exchange listed actively traded classified level inactively traded assets classified level limited partnerships represent investments private equity similar funds valued general partners certain limited partnerships well assets valued using unobservable inputs classified level following table sets forth retirement plans ' investments measured fair value december december quoted prices significant active significant markets observable unobservable identical assets inputs inputs level level level total assets dollars millions shortterm investment funds government agency securities debt instruments equity securities commingled funds insurance contracts assets investments fair value company 's benefit plans unfunded except us commingled funds level million million december december respectively fair value johnson johnson common stock directly held plan assets million total plan assets december million total plan assets december level gains losses table sets forth summary changes fair value plans level assets years ended december december debt equity commingled insurance total dollars millions instruments securities funds contracts assets level balance december realized gains losses unrealized gains losses purchases sales issuances settlements net transfers inout exchange rate changes balance december realized gains losses unrealized gains losses purchases sales issuances settlements net transfers inout exchange rate changes balance december savings plan company voluntary k savings plans designed enhance existing retirement programs covering eligible employees company matches percentage employees contributions consistent provisions plan heshe eligible total company matching contributions plans million million million respectively capital treasury stock changes treasury stock treasury stock amounts millions except treasury stock shares thousands shares amount balance december employee compensation stock option plans repurchase common stock balance december employee compensation stock option plans repurchase common stock balance december employee compensation stock option plans repurchase common stock balance january aggregate shares common stock issued approximately shares end cash dividends paid per share compared dividends per share per share october company announced board directors approved share repurchase program authorizing company purchase billion company 's shares common stock repurchase program time limit may suspended periods discontinued time shares acquired available general corporate purposes company intends finance share repurchase program available cash access capital markets january billion repurchased program july company announced board directors approved share repurchase program authorizing company purchase billion company 's shares common stock share repurchase program completed april accumulated comprehensive income components comprehensive income loss consist following total gain accumulated foreign loss currency gainloss employee derivatives comprehensive dollars millions translation securities benefit plans hedges income loss december net changes december net changes december net changes january amounts accumulated comprehensive income presented net related tax impact foreign currency translation adjusted income taxes relates permanent investments international subsidiaries additional details comprehensive income see consolidated statements comprehensive income details reclassifications accumulated comprehensive income gainloss securities reclassifications released income expense net employee benefit plans reclassifications included net periodic benefit cost see note additional details gainloss derivatives hedges reclassifications earnings recorded account hedged transaction see note additional details international currency translation translation subsidiaries operating nonus dollar currencies company determined local currencies international subsidiaries functional currencies except highly inflationary economies defined compound cumulative rates inflation past three years substantial portion cash flows local currency consolidating international subsidiaries balance sheet currency effects recorded component accumulated comprehensive income equity account includes results translating certain balance sheet assets liabilities current exchange rates accounts historical rates except located highly inflationary economies translation balance sheet accounts highly inflationary economies reflected operating results rollforward changes foreign currency translation adjustments included note net currency transaction gains losses included income expense losses million million million respectively earnings per share following reconciliation basic net earnings per share diluted net earnings per share fiscal years ended january december december millions except per share amounts basic net earnings per share average shares outstanding basic potential shares exercisable stock option plans less shares repurchased treasury stock method convertible debt shares accelerated share repurchase program adjusted average shares outstanding diluted diluted net earnings per share diluted net earnings per share calculation included dilutive effect convertible debt offset related reduction interest expense million aftertax years million year diluted net earnings per share calculation included shares related stock options exercise price options less average market value company 's stock diluted net earnings per share calculation fiscal year ended december included dilutive effect million shares related accelerated share repurchase program associated acquisition synthes inc fiscal year rental expense lease commitments rentals space vehicles manufacturing equipment office data processing equipment operating leases approximately million million million respectively approximate minimum rental payments required operating leases initial remaining noncancelable lease terms excess one year january dollars millions total commitments capital leases significant common stock stock option plans stock compensation agreements january company stockbased compensation plans shares outstanding contracts company 's longterm incentive plan longterm incentive plan longterm incentive plan expired april options restricted shares granted subsequent date longterm incentive plan longterm incentive plan company may issue million shares common stock plus shares canceled expired forfeited issued longterm incentive plan subsequent april shares available future grants longterm incentive plan million end compensation cost charged income plans million million million respectively total income tax benefit recognized income statement sharebased compensation costs million million million respectively total unrecognized compensation cost million million million respectively weighted average period cost recognized years years years respectively sharebased compensation costs capitalized part inventory insignificant periods company settles employee benefit equity issuances treasury shares treasury shares replenished throughout year number shares used settle employee benefit equity issuances stock options stock options expire years date grant vest service periods range months years options granted average high low prices companys common stock new york stock exchange date grant fair value option award estimated date grant using blackscholes option valuation model uses assumptions noted following table grants expected volatility represents blended rate year daily historical average volatility rate week average implied volatility rate based atthemoney traded johnson johnson options life years grants expected volatility represents blended rate year weekly historical overall volatility rate week average implied volatility rate based atthemoney traded johnson johnson options life years grants historical data used determine expected life option riskfree rate based us treasury yield curve effect time grant average fair value options granted respectively fair value estimated based weighted average assumptions riskfree rate expected volatility expected life years expected dividend yield summary option activity plan january december december changes years ending dates presented aggregate weighted intrinsic average exercise value shares thousands outstanding shares price dollars millions shares december options granted options exercised options canceledforfeited shares december options granted options exercised options canceledforfeited shares december options granted options exercised options canceledforfeited shares january total intrinsic value options exercised million million million respectively following table summarizes stock options outstanding exercisable january shares thousands outstanding exercisable average average exercise price range options average life exercise price options exercise price average contractual life remaining years stock options outstanding december december average life years average life years respectively stock options exercisable december december average price average price respectively restricted share units performance share units company grants restricted share units vest service periods range months years company also grants performance share units paid shares johnson johnson common stock end threeyear performance period whether performance share units vest amount vest tied completion service periods range months years achievement threeyear period three equallyweighted goals directly align help drive longterm total shareholder return operational sales adjusted operational earnings per share relative total shareholder return number shares actually earned end thethreeyear period vary based actual performance target number performance share units granted summary restricted share units performance share units activity plans january presented outstanding outstanding restricted share performance shares thousands units share units shares december granted issued canceledforfeited shares december granted issued canceledforfeited shares december granted issued canceledforfeited shares january average fair value restricted share units granted respectively using fair market value date grant fair value restricted share units discounted dividends paid restricted share units vesting period fair value restricted share units issued million million million respectively weighted average fair value performance share units granted calculated using weighted average fair market value three component goals date grant fair values sales earnings per share goals performance share unit estimated date grant using fair market value shares time award discounted dividends paid performance share units vesting period fair value relative total shareholder return goal performance share unit estimated date grant using monte carlo valuation model fair value performance share units issued million million respectively performance share units vested segments business geographic areas sales customers dollars millions consumer united states international total pharmaceutical united states international total medical devices united states international total worldwide total income tax identifiable assets dollars millions consumer pharmaceutical medical devices total less expense allocated segments general corporate worldwide total additions property depreciation plant equipment amortization dollars millions consumer pharmaceutical medical devices segments total general corporate worldwide total sales customers longlived assets dollars millions united states europe western hemisphere excluding us asiapacific africa segments total general corporate non longlived assets worldwide total see note description segments company operates export sales significant company one wholesaler distributing products three segments represented approximately respectively total consolidated revenues company customer represented total revenues amounts allocated segments include interest income expense noncontrolling interests general corporate income expense general corporate includes cash cash equivalents marketable securities medical devices segment includes restructuring charge million intangible asset writedown million related acclarent synthes integration costs million million expense cost associated depuy asrtm hip program includes million inprocess research development expense comprised million million pharmaceutical medical devices segments respectively includes net litigation expense million comprised million pharmaceutical segment million medical devices segment included gain litigation settlement agreement guidant million medical devices segment includes gain billion divestiture cordis business pharmaceutical segment includes gain million us divestiture nucynta positive adjustment billion previous reserve estimates including managed medicaid rebates consumer segment includes gain million divestiture splenda brand includes net litigation expense million comprised million million million medical devices pharmaceutical consumer segments respectively includes million inprocess research development expense comprised million million pharmaceutical medical devices segments respectively medical devices segment includes net gain million divestiture orthoclinical diagnostics business synthes integration costs million million expense cost associated depuy asrtm hip program pharmaceutical segment includes additional year branded prescription drug fee million positive adjustment billion previous reserve estimates includes million net litigation expense comprised million million medical devices pharmaceutical segments respectively includes million synthes integrationtransaction costs medical devices segment includes million inprocess research development expense comprised million million pharmaceutical medical devices segments respectively medical devices segment also includes million expense cost associated depuy asrtm hip program includes million income related adjustments comprised million million consumer pharmaceutical segments respectively longlived assets include property plant equipment net respectively intangible assets goodwill net respectively selected quarterly financial data unaudited selected unaudited quarterly financial data years summarized first second third fourth first second third fourth dollars millions except per share data quarter quarter quarter quarter quarter quarter quarter quarter segment sales customers consumer pharmaceutical medical devices total sales gross profit earnings provision taxes income net earnings basic net earnings per share diluted net earnings per share first quarter includes net litigation gain million aftertax million beforetax million aftertax million beforetax costs associated depuy asrtm hip program second quarter includes net litigation expense million aftertax million beforetax third quarter includes net litigation expense million aftertax million beforetax fourth quarter includes restructuring charge million aftertax million beforetax million aftertax million beforetax impairment inprocess research development synthes integration costs million aftertax million beforetax additionally fourth quarter includes gain cordis divestiture first quarter includes synthes integration costs million aftertax million beforetax million tax benefit associated conor medsystems second quarter includes litigation expense million aftertax million beforetax synthes integration costs million aftertax million beforetax third quarter includes additional year branded prescription drug fee million tax litigation expense million aftertax million beforetax synthes integration costs million aftertax million beforetax million aftertax million beforetax costs associated depuy asrtm hip program additionally fiscal third quarter includes net gain billion aftertax billion beforetax divestiture orthoclinical diagnostics business fourth quarter includes litigation expense primarily related product liability patent litigation million aftertax million beforetax synthes integration costs million aftertax million beforetax million aftertax million beforetax impairment inprocess research development business combinations divestitures certain businesses acquired million cash million liabilities assumed assumed liabilities primarily represent fair value contingent consideration million acquisitions accounted using acquisition method accordingly results operations included financial statements respective dates acquisition acquisitions primarily included xo limited privatelyheld biopharmaceutical company developing antithrombin antibody novira therapeutics inc privately held clinicalstage biopharmaceutical company developing innovative therapies curative treatment chronic hepatitis b virus infection excess purchase price estimated fair value tangible assets acquired amounted million assigned identifiable intangible assets residual recorded goodwill amount approximately million identified value iprd primarily associated acquisitions xo limited novira therapeutics inc value iprd calculated using cash flow projections discounted inherent risk projects iprd related acquisition xo limited million associated recombinant human antibody developed mimic activity human antibody appears produce anticoagulated state without predisposition bleeding probability success factor used reflect inherent clinical regulatory risk discount rate applied iprd related acquisition novira therapeutics inc million associated lead candidate nvr investigational small molecule directacting antiviral oral administration patients hbv inhibits hbv core capsid protein probability success factor used reflect inherent clinical regulatory risk discount rate applied certain businesses acquired million cash million liabilities assumed acquisitions accounted using acquisition method accordingly results operations included financial statements respective dates acquisition acquisitions included covagen ag privatelyheld biopharmaceutical company specializing development multispecific protein therapeutics fynomab technology platform alios biopharma inc privatelyheld clinical stage biopharmaceutical company focused developing therapies viral diseases orsltm electrolyte ready todrink brand jagdale industries ltd excess purchase price estimated fair value tangible assets acquired amounted million assigned identifiable intangible assets residual recorded goodwill amount approximately million identified value iprd associated acquisitions covagen ag alios biopharma inc value iprd calculated using cash flow projections discounted inherent risk projects iprd related acquisition alios biopharma inc alios million associated alios lead compound al orally administered antiviral therapy treatment infants respiratory syncytial virus rsv probability success factor used reflect inherent clinical regulatory risk discount rate applied iprd related acquisition covagen ag million associated covagens lead compound cova currently phase b study psoriasis holding potential treatment broad range inflammatory diseases including rheumatoid arthritis probability success factor used reflect inherent clinical regulatory risk discount rate applied company recorded charge impairment iprd related acquisition covagen ag certain businesses acquired million cash million liabilities assumed acquisitions accounted using acquisition method accordingly results operations included financial statements respective dates acquisition assumed liabilities primarily represent fair value contingent consideration may payable related acquisition aragon pharmaceuticals inc privatelyheld pharmaceutical discovery development company focused drugs treat hormonallydriven cancers per terms agreement additional payments million may paid future based reaching predetermined milestones acquisitions included flexible stenting solutions inc leading developer innovative flexible peripheral arterial venous biliary stents shanghai elsker mother baby co ltd baby care company china aragon pharmaceuticals inc excess purchase price estimated fair value tangible assets acquired amounted million assigned identifiable intangible assets residual recorded goodwill amount approximately million identified value iprd primarily associated acquisitions aragon pharmaceuticals inc iprd related acquisition aragon pharmaceuticals inc million associated aragons androgen receptor antagonist program treatment hormonallydriven cancers value iprd calculated using cash flow projections discounted inherent risk projects probability success factors ranging used reflect inherent clinical regulatory risk discount rate applied company completed acquisition synthes inc purchase price billion cash stock connection acquisition synthes inc company entered two accelerated share repurchase asr agreements company settled remaining liabilities asr agreements company believes transactions asr agreement series related internal transactions consummated tax efficient manner accordance applicable law possible internal revenue service could assert one contrary positions challenge transactions tax perspective challenged amount total purchase price synthes shares could treated subject applicable us tax approximately statutory rate company plus interest supplemental pro forma information accordance us gaap standards related business combinations goodwill intangible assets provided impact aforementioned acquisitions material effect companys results operations cash flows financial position company divestitures included cordis business cardinal health splenda brand heartland food products group us license rights nucynta tapentadol nucynta er tapentadolextendedrelease tablets nucynta tapentadol oral solution pretax gains divestitures businesses approximately billion january assets held sale material company divestitures included orthoclinical diagnostics business carlyle group ky brand reckitt benckiser group plc us certain markets benecol brand raisio plc pretax gains divestitures businesses approximately billion company completed divestiture orthoclinical diagnostics business carlyle group approximately billion company recorded pretax gain approximately billion orthoclinical diagnostics ' results included company 's medical devices segment company divestitures included women 's sanitary protection products us canada caribbean energizer holdings inc rolaids chattem inc doribax rights shionogi sale certain consumer brands certain pharmaceutical products pretax gains divestitures businesses billion legal proceedings johnson johnson certain subsidiaries involved various lawsuits claims regarding product liability intellectual property commercial matters governmental investigations legal proceedings arise time time ordinary course business company records accruals loss contingencies associated legal matters probable liability incurred amount loss reasonably estimated january company determined liabilities associated certain litigation matters probable reasonably estimated company accrued matters continue monitor related legal issue adjust accruals might warranted based new information developments accordance asc litigation regulatory matters discussed loss probable reasonably possible company unable estimate possible loss range loss beyond amounts already accrued amounts accrued legal contingencies often result complex series judgments future events uncertainties rely heavily estimates assumptions ability make estimates judgments affected various factors including whether damages sought proceedings unsubstantiated indeterminate scientific legal discovery commenced complete proceedings early stages matters present legal uncertainties significant facts dispute numerous parties involved company 's opinion based examination matters experience date discussions counsel ultimate outcome legal proceedings net liabilities accrued company 's balance sheet expected material adverse effect company 's financial position however resolution increase accruals one matters reporting period may material adverse effect company 's results operations cash flows period product liability certain subsidiaries johnson johnson involved numerous product liability claims lawsuits involving multiple products claimants cases seek substantial compensatory available punitive damages subsidiaries believe substantial defenses feasible predict ultimate outcome litigation company established accruals product liability claims lawsuits compliance asc based currently available information cases may limited company accrues estimate legal defense costs needed defend matter certain matters company accrued additional amounts estimated costs associated settlements damage losses product liability accruals represent projected product liability thousands claims around world different litigation environments different fact patterns changes accruals may required future additional information becomes available significant cases include depuy asr xl acetabular system depuy asr hip resurfacing system pinnacle acetabular cup system pelvic meshes risperdal xarelto january united states approximately plaintiffs direct claims pending lawsuits regarding injuries allegedly due depuy asr xl acetabular system depuy asr hip resurfacing system respect pinnacle acetabular cup system respect pelvic meshes respect risperdal respect xarelto august depuy orthopaedics inc depuy announced worldwide voluntary recall asr xl acetabular system depuy asr hip resurfacing system used hip replacement surgery claims personal injury beenmade depuy johnson johnson number pending lawsuits expected fluctuate certain lawsuits settled dismissed additional lawsuits filed cases filed federal courts united states organized multidistrict litigation united states district court northern district ohio litigation also filed countries outside united states primarily united kingdom canada australia november depuy reached agreement courtappointed committee lawyers representing asr hip system plaintiffs establish program settle claims eligible asr hip patients united states surgery replace asr hips known revision surgery august settlement covered approximately patients february depuy reached additional agreement would effectively extend existing settlement program asr hip patients revision surgeries august prior february second agreement estimated cover approximately additional patients estimated cost agreements covered existing accruals settlement program expected bring close significant asr hip litigation activity united states however many lawsuits united states remain settlement program address litigation outside united states company continues receive information respect potential costs associated recall worldwide basis company established accruals costs associated depuy asr hip program related product liability litigation changes accruals may required future additional information becomes available claims personal injury also made depuy johnson johnson relating depuy 's pinnacle acetabular cup system used hip replacement surgery number pending product liability lawsuits continues increase company continues receive information respect potential costs anticipated number cases cases filed federal courts united states organized multidistrict litigation united states district court northern district texas litigation also filed countries outside united states primarily united kingdom company established accrual cover defense costs connection product liability litigation associated depuy 's pinnacle acetabular cup system changes accrual may required future additional information becomes available claims personal injury made ethicon inc ethicon johnson johnson arising ethicon 's pelvic mesh devices used treat stress urinary incontinence pelvic organ prolapse number pending product liability lawsuits continues increase company continues receive information respect potential costs anticipated number cases cases filed federal courts united states organized multidistrict litigation united states district court southern district west virginia addition class actions individual personal injury cases claims commenced australia belgium canada england israel italy netherlands scotland venezuela seeking damages alleged injury resulting ethicon 's pelvic mesh devices company established accrual respect product liability litigation associated ethicon 's pelvic mesh products changes accrual may required future additional information becomes available claims personal injury made janssen pharmaceuticals inc johnson johnson arising use risperdal indicated treatment schizophrenia acute manic mixed episodes associated bipolar disorder irritability associated autism related compounds number pending product liability lawsuits continues increase company continues receive information respect potential costs anticipated number cases company established accrual respect product liability litigation associated risperdal changes accrual may required future additional information becomes available claims personal injury made janssen pharmaceuticals inc johnson johnson arising use xarelto oral anticoagulant number pending product liability lawsuits continues increase company continues receive information respect potential costs anticipated number cases cases filed federal courts united states organized multidistrict litigation united states district court eastern district louisiana addition cases filed state courts across united states many cases consolidated state mass tort litigation philadelphia pennsylvania class action lawsuits also filed canada company established accrual respect product liability litigation associated xarelto changes accrual may required future additional information becomes availableintellectual property certain subsidiaries johnson johnson subject time time legal proceedings claims related patent trademark intellectual property matters arising businesses many matters involve challenges coverage andor validity patents various products allegations certain companys products infringe patents third parties although subsidiaries believe substantial defenses challenges allegations respect significant patents assurance outcome matters loss cases could adversely affect ability subsidiaries sell products result loss sales due loss market exclusivity require payment past damages future royalties may result noncash impairment charge associated intangible asset significant matters described medical devices january tyco healthcare group lp tyco us surgical corporation covidien plc filed lawsuit ethicon endosurgery inc ees united states district court district connecticut alleging ees 's harmonic shears infringed three tyco patents case tried july march court ruled ees 's harmonic shears infringed tyco 's patents ordered ees pay damages approximately million declined order injunctive relief ees appealed december united states court appeals federal circuit reversed district court 's ruling found asserted claims invalid july tyco filed motion review united states supreme court july covidien filed another patent infringement lawsuit ees united states district court district connecticut seeking damages preliminary injunction alleging ees 's newest version harmonic scalpels harmonic ace shears harmonic ace shears infringed three tyco patents asserted previous case claims asserted covidien case claims declared invalid december court appeals tyco case discussed november united states supreme court denied tyco 's petition review therefore cases dismissed november roche diagnostics operations inc et al roche filed patent infringement lawsuit lifescan inc lifescan united states district court district delaware alleging lifescan 's onetouch line blood glucose monitoring systems infringe two patents related use microelectrode sensors roche seeking monetary damages injunctive relief september lifescan obtained favorable ruling claim construction precluded finding infringement roche appealed court appeals reversed district court 's ruling claim construction remanded case district court new findings issue december district court ruled lifescan 's favor reinstated original claim construction february roche appealed ruling february oral argument took place court appeals parties awaiting decision june rembrandt vision technologies lp rembrandt filed patent infringement lawsuit johnson johnson vision care inc jjvc united states district court eastern district texas alleging jjvc 's manufacture sale acuvueadvance acuvue oasys hydrogel contact lenses infringe us patent ' patent rembrandt seeking monetary relief case transferred united states district court middle district florida may jury returned verdict holding neither accused lenses infringes ' patent rembrandt appealed august united states court appeals federal circuit affirmed district court 's judgment rembrandt asked district court grant new trial based alleged new evidence july district court denied rembrandts motion rembrandt appealed district court 's denial motion new trial december state israel filed lawsuit district court tel aviv jaffa omrix biopharmaceuticals inc various affiliates omrix lawsuit state claims employee governmentowned hospital inventor several patents related fibrin glue technology employee developed government employee state claims right transfer intellectual property omrix belongs state state seeking damages plus royalties quixil evicel products alternatively transfer patents state case remains active trial date set september lifescan inc lifescan filed lawsuit shasta technologies llc shasta instacare corp pharmatech solutions inc pharmatech conductive technologies inc conductive united states district court northern district california patent infringement false advertising making marketing astrip use lifescan 's onetouch blood glucose meters defendants alleged three lifescan patentsinsuit invalid challenged validity asserted patents united states patent trademark office uspto april defendants brought counterclaims alleged antitrust violations false advertising claims stayed pending resolution patent infringement case validity two patents confirmed uspto uspto determined third patent us patent ' patent invalid lifescan lost appeal decision seeking rehearing lifescan entered settlement agreement shasta conductive motion brought pharmatech summary judgment patent invalidity argued february parties awaiting decision lifescan 's patent infringement false advertising claims scheduled tried august lifescan filed patent infringement lawsuit unistrip technologies llc unistrip united states district court district north carolina may alleging making marketing unistrips strips infringe patents asserted shasta case stayed pending outcome appeal uspto 's decision validity ' patent july unistrip brought lawsuit lifescan united states district court eastern district pennsylvania alleging antitrust violations relating marketing practices lifescan strips march medinol ltd medinol filed patent infringement lawsuit cordis corporation cordis johnson johnson united states district court southern district new york alleging cordis 's sales cypher cypher select stents made united states since willfully infringed four medinol 's patents directed geometry articulated stents medinol seeking damages attorney 's fees trial january district court dismissed case finding medinol unreasonably delayed bringing claims medinol appeal decision september district court denied motion medinol vacate judgment grant new trial medinol 's appeal decision dismissed medinol filed petition review united states supreme court following divestiture cordis company retains liability may result case december bonutti skeletal innovations llc bonutti sued depuy synthes sales inc depuy synthes products inc united states district court district massachusetts alleging depuy synthes 's product line spine implants infringes six patents owned bonutti generally covering wedge implants methods implantation bonutti seeking monetary damages injunctive relief pharmaceutical noramco inc noramco moved intervene several patent infringement lawsuits filed united states district court southern district new york purdue pharma lp others purdue noramco oxycodone customers impax laboratories inc impax teva pharmaceuticals usa inc teva amneal pharmaceuticals llc amneal watson laboratories inc florida watson andrx labs llc andrx lawsuits response defendants ' respective abbreviated new drug applications seeking approval market generic extended release oxycodone products expiration certain purdue patents three asserted patents relate oxycodone processes making oxycodone noramco agreed defend lawsuits behalf impax teva amneal watson andrx april watson andrx entered settlement purdue trial impax teva others took place september noramco defended teva impax november impax entered settlement purdue december teva entered settlement purdue district court issued decision january invalidating relevant purdue patents based decision subsequently dismissed lawsuit amneal parties defended noramco purdue appealed court 's decision february federal circuit affirmed district court decision invalidating purdue patents purdue ultimately prevails appeal invalidity decision reinstitute action amneal december purdue filed another patent infringement action amneal district delaware asserting among others three abovereferenced patents newly issued patent relating oxycodone processes making oxycodone johnson johnson acquired prostate cancer business aragon pharmaceuticals inc aragon including arn compound tested treatment prostate cancer september prior acquisition may medivation inc medivation sued aragon university california seeking rights arn december state court granted summary judgment aragon medivation 's claims awarding rights arn compound aragon january court dismissed case aragon medivation appealed remicade related cases september jbi nyu langone medical center nyu medical center received office action united states patent trademark office uspto rejecting claims us patent relating remicade ' patent reexamination proceeding instituted third party ' patent coowned jbi nyu medical center nyu medical center granted jbi exclusive license nyu medical center 's rights patent currently ' patent united states expires september jbi responded rejection december august jbi nyu medical center received rejection jbi responded rejection filing amendment november jbi 's petition enter amendment granted application returned examiner issuance new office action occurred february rejecting patent jbi responded rejection april uspto issued action maintaining rejection ' patent may jbi filed notice appeal uspto 's patent trial appeal board appeal currently pending ' patent remains valid enforceable patent undergoes reexamination uspto jbi continue defend patent necessary pursue available appeals august celltrion filed fda approval make sell biosimilar version remicade march jbi filed lawsuit united states district court district massachusetts celltrion hospira seeking declaratory judgment biosimilar product seeking fda approval new biologics price competition innovation act bpcia infringes potentially infringes six jbi patents jbi also seeking declaratory judgment defendants failed comply certain procedural requirements bpcia addition jbi moved preliminary permanent injunction prohibit celltrion hospira launching biosimilar product days given jbi notice commercial marketing notice given fda approval celltrion 's product also march jbi moved stay proceedings district court respect patent pending uspto reexamination proceeding august jbi also filed motion seeking district court 's permission file patent infringement lawsuit asserting us patent ' patent celltrion manufacturer cell culture media celltrion uses make biosimilar product although ' patent already asserted existing lawsuit would expand claims include use cell media made united states manufacture celltrion 's biosimilar february celltrion hospira agreed launch biosimilar product june ' ' patents two remaining patents lawsuit light representation federal circuit court appeals expected decide issue unrelated similar case june th court denied jbi 's motion preliminary injunction noted jbi may renew motion following court appeals decision necessary court appeals fails decide issue june th addition february celltrion hospira filed motion summary judgment invalidity patent march hospira healthcare corporation hospira filed impeachment proceeding kennedy institute rheumatology kennedy challenging validity canadian patent related remicade feldman patent exclusively licensed janssen biotech inc jbi october kennedy along jbi janssen inc cilag gmbh international affiliates jbi filed counterclaim infringement celltrion healthcare co ltd celltrion inc together celltrion hospira counterclaim alleges products described celltrions hospiras marketing applications health canada subsequent entry biologics seb remicade would infringe feldman patents owned kennedy discovery patent action ongoing trial scheduled september january health canada approved celltrions seb remicade allowing celltrion market biosimilar version remicade canada regardless pending patent action june hospira received approval seb remicade july janssen inc janssen filed lawsuit compel canadian minister health withdraw notice compliance hospiras seb hospira serve notice allegation janssen address patent listed janssen patent register march parties entered settlement agreement whereby health canada agreed consent judgment setting aside hospiras notice compliance subject health canada 's right appeal appeal filed june nevertheless hospira began marketing biosimilar version remicade distributor celltrion 's notice compliance remicade related patents discussed found invalid patent could relied upon prevent introduction biosimilar versions remicade biosimilar versions remicade introduced certain markets outside united states resulting reduction sales remicade markets timing possible introduction biosimilar version remicade united states subject enforcement ofpatent rights approval fda compliance day notice provisions bpcia february arthritis advisory committee fda recommended approval celltrions investigational biosimilar version remicade vote across eligible indications united states risk competitor could launch biosimilar version remicade following fda approval subject compliance day notice provisions bpcia even though one valid patents place introduction us market biosimilar version remicade result reduction us sales remicade litigation filers abbreviated new drug applications andas following summarizes lawsuits pending generic companies filed abbreviated new drug applications andas fda undertaken similar regulatory processes outside united states seeking market generic forms products sold various subsidiaries johnson johnson prior expiration applicable patents covering products andas typically include allegations noninfringement invalidity unenforceability applicable patents event subsidiaries successful actions statutory month stays andas expire united states district court rulings obtained thirdparty companies involved ability upon approval fda introduce generic versions products issue market resulting potential substantial market share revenue losses products may result noncash impairment charge associated intangible asset addition time time subsidiaries may settle actions settlements involve introduction generic versions products issue market prior expiration relevant patents prezista number generic companies filed andas seeking approval market generic versions prezista november tibotec inc tibotec llc tibotec pharmaceuticals janssen rd ireland collectively tibotec filed patent infringement lawsuit lupin ltd lupin pharmaceuticals inc collectively lupin mylan inc mylan pharmaceuticals inc collectively mylan united states district court district new jersey response lupin 's mylan 's respective andas seeking approval market generic versions tibotec 's prezista product expiration tibotec 's patent relating prezista lupin mylan filed counterclaims alleging noninfringement invalidity july tibotec filed another patent infringement lawsuit lupin united states district court district new jersey response lupin 's supplement anda add new dosage strengths proposed product august tibotec gd searle company gd searle filed patent infringement lawsuit lupin mylan response notice letters advising andas seeking approval market generic versions tibotec 's prezista product expiration two additional patents relating prezista tibotec exclusively licenses gd searle september court consolidated lawsuits referred first consolidated action approved new drug application prezista transferred tibotec inc janssen products lp december janssen products lp janssen rd ireland collectively janssen added several patents exclusively license gd searle first consolidated action mylan lupin june janssen gd searle dismissed claims relating patents owned gd searle lupin mylan based parties agreement seek fda approval respective andas november expiration gd searle patents trial regarding remaining patents first consolidated action court issued decision august favor janssen holding asserted patents valid would infringed lupin 's mylan 's marketing proposed products mylan lupin filed appeal july janssen filed patent infringement lawsuit mylan united states district court district new jersey alleging infringement united states patent november janssen mylan entered confidential settlement pursuant settlement agreement parties process seeking dismissal action addition appeal august decision relates mylan dismissed remanded district court parties seeking modification courts order accordance settlement agreement may lupin notified janssen filed anda seeking approval market new dosage strength generic version prezista response janssen filed patent infringement lawsuit united states district court district new jersey alleging lupin 's new dosage strength would infringe patents janssen asserting lupin original action march janssen filed patent infringement lawsuit lupin united states district court district new jersey alleging infringement united states patent patent january court consolidated lawsuits referred second consolidated action stayed pending lupin 's appeal court 's decision first consolidated action april lupin filed inter partes review uspto seeking invalidate patent october uspto denied lupin 's petition january janssen received patent notice lupin advising lupin amended anda reflect new formulation darunavir lupin alleges infringe relevant janssen patents february janssen filed lawsuit asserting patents lupin united states district court district new jersey addition january lupin filed motion stay deactivate appeal abovereferenced august decision remand matter district court lupin intends modify district court order injunction allow lupin market new formulation darunavir expiration relevant patents janssen filed patent infringement lawsuit hetero drugs ltd unit iii hetero usa inc march united states district court district new jersey alleging infringement united states patent nos october parties stipulated consent judgment wherein hetero defendants admitted patentsinsuit valid would infringed manufacture importation use sale heteros anda product agreed injunction respect product life patentsinsuit hetero reserved right develop noninfringing darunavir products processes august janssen filed patent infringement lawsuits cipla ltd cipla usa inc collectively cipla united states district courts districts new jersey delaware response ciplas anda seeking approval market generic version janssens prezista product expiration certain janssens patents relating prezista cipla filed counterclaims seeking declarations noninfringement invalidity patentsinsuit may janssen cipla entered settlement agreement response notice allegation seeking approval market generic version prezista canada expiration canadian patent janssen inc janssen rd ireland filed notice application mylan pharmaceuticals ulc july december janssen rd ireland transferred prezista patents janssen sciences ireland uc janssen sciences ireland uc substituted janssen rd ireland plaintiff referenced actions february parties entered confidential settlement notice application dismissed january janssen inc janssen sciences ireland uc filed notice application teva canada limited response notice allegation seeking approval market generic version prezista expiration canadian patent october parties entered settlement wherein teva canada limited agreed withdraw notice allegation without prejudice file new one future janssen inc janssen sciences ireland uc agreed dismiss notice application lawsuits janssen sought seeking order enjoining defendants marketing generic versions prezista expiration relevant patents concerta may alza corporation alza janssen pharmaceuticals inc jpi filed patent infringement lawsuit united states district court district west virginia mylan inc mylan pharmaceuticals inc mylan response anda seeking approval market generic version concerta expiration united states patent ' patent mylan filed counterclaims seeking declarations invalidity noninfringement patentsinsuit may mylan sought leave add counterclaim invalidity noninfringement us patent ' patent court denied mylan 's motion july mylan filed declaratory judgment action eastern district pennsylvania seeking declaration invalidity noninfringement ' patent october parties entered confidential settlement west virginia pennsylvania actions december janssen inc alza filed notice application actavis pharma company actavis response notice allegation seeking approval market generic version concerta expiration canadian patent patent hearing scheduled september february janssen inc alza filed notice application apotex inc apotex response notice allegation seeking approval market generic version concerta expiration ' patent august janssen inc alza voluntarily dismissed notice applicationin lawsuits alza andor jpi sought seeking order enjoining defendants marketing generic versions concerta expiration relevant patents zytiga june july janssen biotech inc jbi received notices paragraph iv certification several companies advising respective andas seeking approval generic version zytiga expiration one patents relating zytiga july jbi janssen oncology inc janssen research development llc collectively janssen btg international ltd btg filed patent infringement lawsuit united states district court district new jersey several generic anda applicants certain affiliates andor suppliers response respective andas seeking approval market generic version zytiga expiration united states patent nos ' patent expiring december andor ' patent expiring august generic companies include actavis laboratories fl inc actavis amneal pharmaceuticals llc amneal pharmaceuticals new york llc collectively amneal apotex inc apotex corp collectively apotex citron pharma llc citron dr reddys laboratories ltd dr reddys laboratories inc collectively dr reddy 's mylan pharmaceuticals inc mylan inc collectively mylan par pharmaceuticals inc par pharmaceutical companies inc collectively par sun pharmaceutical industries ltd sun pharmaceuticals industries inc collectively sun teva pharmaceuticals usa inc teva wockhardt bio ag wockhardt usa llc wockhardt ltd collectively wockhardt westward pharmaceutical corp westward hikma pharmaceuticals llc hikma court entered stay new jersey lawsuit par citron agreed bound decision defendants new jersey action february new jersey court set trial date october august janssen btg filed additional jurisdictional protective lawsuit mylan defendants united states district court northern district west virginia october mylan filed motion dismiss new jersey lawsuit lack personal jurisdiction improper venue february west virginia court stayed west virginia case pending decision mylan 's motion dismiss new jersey lawsuit set conditional trial date february court dismiss west virginia lawsuit mylan 's motion dismiss new jersey denied august jbi received notice paragraph iv certification hetero usa inc us regulatory agent hetero labs limited unitv division hetero labs limited collectively hetero advising heteros anda seeking approval generic version zytiga expiration ' patent september janssen btg filed amended complaint new jersey lawsuit allege infringement ' patent hetero filing abovereferenced lawsuits triggered stay october fda grant final approval generics ' andas unless earlier district court decision finding patentsinsuit invalid infringed december amerigen pharmaceuticals limited filed petition inter partes review uspto seeking invalidate ' patent lawsuits janssen seeking order enjoining defendants marketing generic versions zytiga expiration relevant patents complera august september janssen pharmaceutica nv janssen sciences ireland uc collectively janssen gilead sciences inc gilead sciences ireland uc collectively gilead filed patent infringement lawsuits united states district court district delaware west virginia mylan inc mylan pharmaceuticals inc collectively mylan response anda seeking approval market generic version complera expiration united states patent nos september mylan filed answer west virginia action included counterclaims seeking declarations invalidity noninfringement patentsinsuit well united states patent september mylan filed motion dismiss delaware lawsuit lack personal jurisdiction january janssen gilead filed first amended complaint new jersey action adding claims patent infringement respect united states patent nos addition new jersey action court dismissed mylans motion dismiss set trial date february west virginia action court set trial date december february mylan renewed motion dismiss lack jurisdictionin lawsuits janssen seeking order enjoining defendants marketing generic versions complera expiration relevant patents xarelto number generic companies filed andas seeking approval market generic versions xarelto october janssen pharmaceuticals inc jpi bayer pharma ag bayer intellectual property gmbh collectively bayer filed patent infringement lawsuit aurobindo pharma limited aurobindo pharma usa inc breckenridge pharmaceutical inc micro labs usa inc micro labs ltd mylan pharmaceuticals inc mylan inc prinston pharmaceutical inc sigmapharm laboratories llc torrent pharmaceuticals limited torrent pharma inc united states district court district delaware response parties respective andas seeking approval market generic versions xarelto expiration bayers united states patent nos relating xarelto jpi exclusive licensee asserted patents jpi seeking order enjoining defendants marketing generic versions xarelto expiration relevant patents november mylan moved dismiss action december jpi bayer mylan stipulated agreed dismiss claims mylan inc suspend briefing argument mylan 's motion dismiss pending appeals relating personal jurisdiction mylan pharmaceuticals inc district delaware january jpi bayer received paragraph iv notice invagen pharmaceuticals inc invagen advising seeking fda approval generic xarelto product expiration relevant patents february jpi bayer filed patent infringement action invagen asserting xarelto patents asserted original case invagen case consolidated original case court set trial date march government proceedings like companies pharmaceutical medical devices industries johnson johnson certain subsidiaries subject extensive regulation national state local government agencies united states countries operate result interaction government agencies ongoing significant litigation brought investigations conducted government agencies listed possible criminal charges substantial fines andor civil penalties damages could result government investigations litigation average wholesale price awp litigation johnson johnson several pharmaceutical subsidiaries jj awp defendants along numerous pharmaceutical companies defendants series lawsuits state federal courts involving allegations pricing marketing certain pharmaceutical products amounted fraudulent otherwise actionable conduct among things companies allegedly reported inflated average wholesale price awp drugs issue payors alleged used awps calculating provider reimbursement levels many cases federal actions state actions removed federal court consolidated pretrial purposes multidistrict litigation mdl united states district court district massachusetts plaintiffs cases included three classes private persons entities paid portion purchase drugs issue based awp state government entities made medicaid payments drugs issue based awp june trial merits mdl court dismissed claims two plaintiff classes jj awp defendants march court dismissed claims third class jj awp defendants without prejudice awp cases brought various attorneys general proceeded trial manufacturers several state cases certain subsidiaries johnson johnson settled including case alaska settled april cases still pending illinois new jersey wisconsin utah cases illinois new jersey wisconsin yet proceeded trial utah claims brought attorney general dismissed court state may appeal dismissal conclusion similar pending matters defendants awp case jj awp defendants brought attorney general commonwealth pennsylvania tried commonwealth court court found commonwealth 's favor regard certain claims pennsylvania unfair trade practices consumer protection law utpl entered injunction awarded million restitution million civil penalties court found jj awp defendants ' favor commonwealth 's claims unjust enrichment misrepresentationfraud civil conspiracy certain commonwealth 's claims utpl jjawp defendants appealed commonwealth court 's utpl ruling june pennsylvania supreme court vacated judgment entered commonwealth court remanded case proceedings remand january commonwealth court dismissed monetary awards jj awp defendants march ruling appealed back pennsylvania supreme court december pennsylvania supreme court affirmed order commonwealth court dismissing monetary awards jj awp defendants risperdal november johnson johnson subsidiary janssen pharmaceuticals inc jpi finalized previously disclosed settlement agreements united states department justice fortyfive states resolving federal investigations state medicaid claims related past promotional practices risperdal matters jpi also settled alleged consumer fraud claims connection sale marketing risperdal thirtysix states district columbia september addition actions attorneys general several states brought actions jpi related sale marketing risperdal seeking one following remedies reimbursement medicaid public funds risperdal prescriptions written offlabel use compensation treating citizens alleged adverse reactions risperdal civil fines penalties violations state false claims acts consumer fraud statutes punitive damages relief relating alleged unfair business practices certain actions also sought injunctive relief relating promotion risperdal many actions claims brought state attorneys general settled either individually part settlements described cases brought attorneys general mississippi kentucky settled december without admission wrongdoing part jpi state cases went judgment trial discussed attorney general west virginia commenced lawsuit janssen pharmaceutica inc jpi based claims alleged consumer fraud duragesic well risperdal jpi found liable damages assessed million jpi filed appeal november west virginia supreme court appeals reversed trial court 's decision december attorney general west virginia dismissed case related risperdal without payment thereafter jpi settled case insofar related duragesic attorney general louisiana filed multicount complaint janssen pharmaceutica inc jpi johnson johnson later added defendant case tried october issue tried jury whether johnson johnson jpi violated state 's medical assistance program integrity law act misrepresentations allegedly made mailing november dear health care professional letter regarding risperdal jury returned verdict jpi johnson johnson violated act awarded million damages trial judge subsequently awarded attorney general counsel fees expenses amount million january louisiana supreme court reversed district courts judgment favor attorney general rendered judgment favor johnson johnson jpi april louisiana supreme court denied attorney general 's petition seeking rehearing appellate arguments resulting final dismissal case office general counsel commonwealth pennsylvania filed lawsuit janssen pharmaceutica inc jpi multicount complaint related janssen pharmaceutica 's sale risperdal commonwealth 's medicaid program trial occurred june trial judge dismissed case close plaintiff 's evidence commonwealth filed appeal july pennsylvania appeals court upheld dismissal commonwealth 's case attorney general south carolina filed lawsuit johnson johnson janssen pharmaceutica inc jpi several counts march matter tried jury liability time lawsuit limited claims violation south carolina unfair trade practices act including among others questions whether johnson johnson jpi engaged unfair deceptive acts practices conduct trade commerce distributing november dear health care professional letter regarding risperdal use product 's fdaapproved label jury found favor johnson johnson jpi june court awarded civil penalties approximately million jpi jpi appealed judgment february south carolina supreme court affirmed trial courts decision part reversed part remanded case back trial court net effect decision reduce judgment approximately million plus interest first fiscal quarter company accrued million march jpi filed petition rehearing july south carolina supreme court granted petition filed substituted opinion new opinion reduced judgment approximately million approximately million january united states supreme court denied jpi 's request review putting end casein april lawsuit brought attorney general arkansas jury found jpi johnson johnson court imposed penalties amount approximately billion january trial court awarded attorney fees approximately million jpi johnson johnson appealed awards arkansas supreme court march arkansas supreme court dismissed states claim arkansas medicaid fraud false claims act well approximately billion penalties reversed remanded claim arkansas deceptive trade practices act april arkansas supreme court rejected petition state rehearing case may matter settled million mcneil consumer healthcare starting june mcneil consumer healthcare division mcneilppc inc johnson johnson consumer inc mcneil consumer healthcare division mcneil consumer healthcare certain affiliates including johnson johnson companies received grand jury subpoenas united states attorney 's office eastern district pennsylvania requesting documents broadly relating recalls various products mcneil consumer healthcare fda inspections fort washington pennsylvania lancaster pennsylvania manufacturing facilities well certain documents relating recalls small number products subsidiaries addition february government served mcneilppc inc mcneilppc civil investigative demand seeking records relevant investigation determine violation federal false claims act march mcneilppc entered guilty plea united states district court eastern district pennsylvania misdemeanor violation us food drug cosmetic act mcneil ppc agreed pay million fine million forfeiture resolve matter companies also received civil investigative demands multiple state attorneys general offices broadly relating mcneil recall issues companies continue cooperate inquiries coordinated multistate coalition resolution reached multistate coalition possible individual state attorneys general offices may file civil monetary claims companies january oregon attorney general filed civil complaint johnson johnson mcneilppc mcneil healthcare llc state court alleging civil violations oregon unlawful trade practices act relating earlier recall mcneil otc product november state court granted motion companies dismiss oregon 's complaint entirety prejudice oregon appealed decision november court appeals state oregon reversed trial court reinstated oregon 's consumer protection claims december companies filed petition review oregon supreme court opioids litigation along pharmaceutical companies johnson johnson jj janssen pharmaceuticals inc jpi named two lawsuits alleging claims related marketing opioids including duragesicnucynta nucynta er may santa clara orange counties california counties filed complaint state court orange county california numerous pharmaceutical manufacturers including jj jpi alleging claims related opioid marketing practices including false advertising unfair competition public nuisance counties seek injunctive monetary relief february defendants filed motions challenging sufficiency complaint august court stayed case fda concludes ongoing inquiry safety effectiveness longterm opioid treatment june city chicago filed complaint cook county circuit court group pharmaceutical manufacturers including jj jpi alleging number claims related opioid marketing practices including consumer fraud violations false claims seeking injunctive monetary relief case later removed united states district court northern district illinois december jj jpi filed motion dismiss city chicago 's first amended complaint failure state claim november jj jpi filed motion dismiss city chicago 's second amended complaint failure state claim september tennessee attorney general division consumer affairs issued request information jpi pharmaceutical companies related opioids marketing practices august new hampshire attorney general consumer protection antitrust bureau issued subpoena jpi pharmaceutical companies related opioids marketing practices jpi objected private contingent fee counsels participation investigation states behalf october state moved enforce subpoenain december state mississippi filed complaint chancery court first judicial district hinds county group pharmaceutical manufacturers including jj jpi alleging number claims related opioid marketing practices state mississippi seeking penalties injunctive monetary relief september synthes inc synthes received civil investigative demand issued pursuant false claims act united states attorney 's office eastern district pennsylvania demand sought information regarding allegations fellowships offered hospitals exchange agreements purchase products synthes produced documents information response demand cooperating inquiry may acclarent inc acclarent received subpoena united states attorney 's office district massachusetts requesting documents broadly relating sales marketing alleged offlabel promotion acclarent relieva stratus microflow spacer product stratus spacer april indictment filed united states district court district massachusetts charging former presidentceo vice president sales acclarent former acclarent officers indictment charges former acclarent officers various violations related offlabel promotion stratus spacer allegations former acclarent officers relate development sale marketing stratus spacer well actions allegedly taken former acclarent officers connection acquisition acclarent ethicon inc charges acclarent ethicon inc johnson johnson august depuy orthopaedics inc depuy inc depuy synthes inc johnson johnson services inc companies received informal request united states attorney 's office district massachusetts civil division united states department justice united states production materials relating asr xl hip device july united states notified united states district court district massachusetts declined intervene qui tam case filed pursuant false claims act companies district court issued order august publicly unsealed united states ' declination notice however complaint matter remains seal addition october group state attorneys general issued civil investigative demands relating development sales marketing several depuy orthopaedics incs hip products july oregon department justice investigating matters independently states announced settlement asr xl hip device investigation total payment million state oregon october johnson johnson contacted california attorney general 's office regarding multistate attorney general investigation marketing surgical mesh products hernia urogynecological purposes johnson johnson 's subsidiary ethicon inc ethicon johnson johnson ethicon since entered series tolling agreements states district columbia participating multistate investigation responded civil investigative demands served certain participating states states seeking monetary injunctive relief december therakos inc therakos formerly subsidiary johnson johnson part orthoclinical diagnostics inc ocd franchise received letter civil division united states attorney 's office eastern district pennsylvania informing therakos united states attorney 's office investigating sales marketing uvadex methoxsalen uvar xts system period present united states attorney 's office requested ocd johnson johnson preserve documents could relate investigation therakos subsequently acquired affiliate gores capital partners iii lp january ocd johnson johnson retain certain liabilities may result investigation activity occurred prior sale therakos march united states attorneys office requested johnson johnson produce certain documents johnson johnson cooperating request following divestiture ocd johnson johnson retains ocds portion liability may result investigation activity occurred prior sale therakos recent years johnson johnson received numerous requests variety united states congressional committees produce information relevant ongoing congressional inquiries policy johnson johnson cooperate inquiries producing requested informationgeneral litigation september johnson johnson filed lawsuit guidant corporation guidant united states district court southern district new york alleging guidant breached provisions merger agreement johnson johnson guidant june guidant filed motion summary judgment july judge denied guidants motion trial concluded january february decision issued court johnson johnson guidant entered settlement agreement pursuant guidant agreed pay johnson johnson million agreed sue johnson johnson affiliates patent infringement regarding certain stent products johnson johnson dismissed action guidant prejudice company recorded gain associated transaction fiscal first quarter june following public announcement orthoclinical diagnostics inc ocd received grand jury subpoena united states department justice antitrust division connection investigation since closed multiple class action complaints filed ocd direct purchasers seeking damages alleged price fixing cases consolidated pretrial purposes united states district court eastern district pennsylvania blood reagent antitrust litigation following divestiture ocd johnson johnson retains liability may result cases august district court granted motion filed plaintiffs class certification april united states court appeals third circuit reversed class certification ruling remanded case district court proceedings october district court granted motion plaintiffs class certification september johnson johnson johnson johnson inc mcneil consumer healthcare division johnson johnson inc received notice civil claim filed nick field supreme court british columbia canada bc civil claim bc civil claim putative class action brought behalf persons reside british columbia purchased period september december one various mcneil infants ' children 's overthecounter medicines manufactured fort washington facility bc civil claim alleges defendants violated bc business practices consumer protection act canadian statutes common laws selling medicines allegedly safe andor effective comply canadian good manufacturing practices class certification hearing scheduled october adjourned currently date set hearing august united states customs border protection us cbp issued penalty notice janssen ortho llc janssen ortho assessing penalties alleged improper classification darunavir ethanolate prezista connection importation united states october janssen ortho submitted petition relief response penalty notice may us cbp issued amended penalty notice assessing substantial penalties janssen ortho filed petition relief july march costco wholesale corporation costco filed complaint johnson johnson vision care inc jjvci united states district court northern district california alleging antitrust claims unlawful vertical price fixing agreement jjvci costco unnamed distributors retailers costco alleges alleged agreements harmed competition causing increases price costco customers pay jjvci contact lenses costco seeking injunction monetary damages june case transferred united states district court middle district florida along related class action cases described november court denied jjvci motion dismiss march april putative class action complaints filed contact lens patients number courts around united states johnson johnson vision care inc jjvci contact lens manufacturers distributors retailers alleging vertical horizontal conspiracies fix retail prices contact lenses complaints alleged manufacturers reached agreements certain distributors retailers concerning prices contact lenses could sold consumers plaintiffs seeking damages class action cases transferred united states district court middle district florida june along related case filed costco wholesale corporation described plaintiffs filed consolidated class action complaint november december jjvci defendants filed motions dismiss april johnson johnson vision care inc jjvci filed complaint united states district court district utah state utah seeking declaratory judgment law passed state ban unilateral pricingpolicies solely contact lens market violates commerce clause united states constitution court denied jjvci 's motion preliminary injunction jjvci appealed argument appeal held august april adimmune corporation ltd adimmune commenced arbitration international court arbitration international chamber commerce crucell switzerland ag janssen vaccines ag crucell holland bv collectively crucell adimmune claims crucell breached certain agreements relating supply flu antigen crucell ceased purchasing flu antigen adimmune december adimmune filed statement claim seeking monetary damages august two thirdparty payors filed purported class action united states district court eastern district louisiana janssen research development llc janssen ortho llc janssen pharmaceuticals inc ortho mcneiljanssen pharmaceuticals johnson johnson well certain bayer entities alleging defendants improperly marketed promoted xarelto safer effective less expensive alternative medications failing fully disclose risks complaint seeks damages unspecified amount johnson johnson subsidiaries also parties number proceedings brought comprehensive environmental response compensation liability act commonly known superfund comparable state local foreign laws primary relief sought cost past andor future remediation restructuring company announced restructuring actions medical devices segment better serve needs patients customers todays evolving healthcare marketplace company undertaking actions strengthen gotomarket model accelerate pace innovation prioritize key platforms geographies streamline operations maintaining high quality standards company estimates connection plans record pretax restructuring charges approximately billion billion expected incurred fiscal fourth quarter company recorded pretax charge million million included cost products sold million restructuring charge consists severance costs million asset writeoffs million million costs primarily related supply contracts additionally part plan company expects restructuring actions result position eliminations approximately percent medical devices segments global workforce next two years subject consultation procedures countries required company estimates approximately one half cumulative pretax costs result cash outlays including approximately million employee severance approximately one half cumulative pretax costs noncash relating primarily facility rationalization inventory writeoffs intangible asset writeoffs following table summarizes severance charges associated spending fiscal year ended dollars millions severance asset writeoffs total restructuring charge current year activity reserve balance january cash outlays severance expected substantially paid next months accordance company 's plans local laws report independent registered public accounting firm shareholders board directors johnson johnson opinion accompanying consolidated balance sheets related consolidated statements earnings statements comprehensive income statements equity statements cash flows present fairly material respects financial position johnson johnson subsidiaries january december results operations cash flows three years period ended january conformity accounting principles generally accepted united states america also opinion company maintained material respects effective internal control financial reporting january based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission coso company 's management responsible financial statements maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying management 's report internal control financial reporting responsibility express opinions financial statements company 's internal control financial reporting based integrated audits conducted audits accordance standards public company accounting oversight board united states standards require plan perform audits obtain reasonable assurance whether financial statements free material misstatement whether effective internal control financial reporting maintained material respects audits financial statements included examining test basis evidence supporting amounts disclosures financial statements assessing accounting principles used significant estimates made management evaluating overall financial statement presentation audit internal control financial reporting included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk audits also included performing procedures considered necessary circumstances believe audits provide reasonable basis opinions discussed note consolidated financial statements company changed manner classifies deferred tax assets liabilities company 's internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles company 's internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company ii provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company iii provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition company 's assets could material effect financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate pricewaterhousecoopers llp pricewaterhousecoopers llp florham park new jersey february managements report internal control financial reporting section sarbanesoxley act management required assess effectiveness companys internal control financial reporting end fiscal year report based assessment whether companys internal control financial reporting effective management company responsible establishing maintaining adequate internal control financial reporting companys internal control financial reporting designed provide reasonable assurance reliability companys financial reporting preparation external financial statements accordance generally accepted accounting principles internal controls financial reporting matter well designed inherent limitations therefore internal control financial reporting determined effective provide reasonable assurance respect financial statement preparation may prevent detect misstatements moreover projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate companys management assessed effectiveness companys internal control financial reporting january making assessment company used criteria established committee sponsoring organizations treadway commission coso internal controlintegrated framework criteria areas control environment risk assessment control activities information communication monitoring companys assessment included extensive documenting evaluating testing design operating effectiveness internal controls financial reporting based companys processes assessment described management concluded january companys internal control financial reporting effective effectiveness companys internal control financial reporting january audited pricewaterhousecoopers llp independent registered public accounting firm stated report appears herein alex gorsky dominic j caruso alex gorsky dominic j caruso chairman board directors vice president finance chief executive officer chief financial officer shareholder return performance graphs set forth line graphs comparing cumulative total shareholder return companys common stock periods five years ten years ending december cumulative total return standard poors stock index standard poors pharmaceutical index standard poors health care equipment index graphs tables assume invested december december companys common stock standard poors stock index standard poors pharmaceutical index standard poors health care equipment index dividends reinvested year shareholder return performance jj vs indices johnson johnson sp index sp pharmaceutical index sp healthcare equipment index year shareholder return performance jj vs indices johnson johnson sp index sp pharmaceutical index sp healthcare equipment index item changes disagreements accountants accounting financial disclosure applicable item controls procedures disclosure controls procedures end period covered report company evaluated effectiveness design operation disclosure controls procedures companys disclosure controls procedures designed ensure information required disclosed company reports files submits exchange act recorded processed summarized reported within time periods specified secs rules forms disclosure controls procedures include without limitation controls procedures designed ensure information required disclosed company reports files submits exchange act accumulated communicated companys management including principal executive principal financial officers persons performing similar functions appropriate allow timely decisions regarding required disclosure alex gorsky chairman chief executive officer dominic j caruso vice president finance chief financial officer reviewed participated evaluation based evaluation messrs gorsky caruso concluded end period covered report companys disclosure controls procedures effective reports internal control financial reporting information called item incorporated herein reference managements report internal control financial reporting attestation regarding internal controls financial reporting included report independent registered public accounting firm included item report changes internal control financial reporting fiscal quarter ended january changes companys internal control financial reporting identified connection evaluation required rules exchange act materially affected reasonably likely materially affect companys internal control financial reporting company implementing multiyear enterprisewide initiative integrate simplify standardize processes systems human resources information technology procurement supply chain finance functions enhancements support growth companys financial shared service capabilities standardize financial systems initiative response identified deficiency weakness companys internal control financial reporting response initiative company continue align streamline design operation financial control environment item b information applicable part iii item directors executive officers corporate governance information called item incorporated herein reference discussion audit committee caption corporate governance board committees material captions item election directors stock ownership section compliance section beneficial ownership reporting compliance proxy statement material caption executive officers registrant part report companys code business conduct covers employees including chief executive officer chief financial officer controller meets requirements sec rules promulgated section sarbanesoxley act code business conduct available companys website wwwinvestorjnjcomgov policiescfm copies available shareholders without charge upon written request secretary companys principal executive offices substantive amendment code business conduct waiver code granted chief executive officer chief financial officer controller posted companys website wwwinvestorjnjcomgovcfm within five business days retained website least one year addition company adopted code business conduct ethics members board directors executive officers code business conduct ethics members board directors executive officers available companys website wwwinvestorjnjcomgovpoliciescfm copies available shareholders without charge upon written request secretary companys principal executive offices substantive amendment thecode waiver code granted member board directors executive officer posted companys website wwwinvestorjnjcomgovcfm within five business days retained website least one year item executive compensation information called item incorporated herein reference material captions item election directors director compensation fiscal compensation committee report compensation discussion analysis executive compensation tables proxy statement material incorporated herein reference material caption compensation committee report proxy statement shall deemed furnished filed report shall deemed incorporated reference filing securities act amended securities exchange act amended result furnishing except extent company specifically incorporates reference item security ownership certain beneficial owners management related stockholder matters information called item incorporated herein reference material caption stock ownership section compliance proxy statement note common stock stock option plans stock compensation agreements notes consolidated financial statements item report equity compensation plan information following table provides certain information january concerning shares companys common stock may issued existing equity compensation plans number securities weighted issued upon average exercise exercise price number securities outstanding outstanding remaining available options options future issuance equity plan category rights rights compensation plans equity compensation plans approved security holders equity compensation plans approved security holders total included category following equity compensation plans approved companys shareholders longterm incentive plan longterm incentive plan column excludes shares reflected column number securities issued upon exercise outstanding options rights longterm incentive plan expired april options restricted shares granted subsequent date longterm incentive plan item certain relationships related transactions director independence information called item incorporated herein reference material captions corporate governance director independence related party transactions proxy statement item principal accountant fees services information called item incorporated herein reference material caption ratification appointment independent registered public accounting firm proxy statement part iv item exhibits financial statement schedules following documents filed part report financial statements consolidated balance sheets end fiscal years consolidated statements earnings fiscal years consolidated statements comprehensive income fiscal years consolidated statements equity fiscal years consolidated statements cash flows fiscal years notes consolidated financial statements report independent registered public accounting firm schedules omitted applicable required information included financial statements notes exhibits required filed item l regulation sk information called item incorporated herein reference exhibit index report signatures pursuant requirements section securities exchange act registrant duly caused report signed behalf undersigned thereunto duly authorized date february johnson johnson registrant gorsky gorsky chairman board directors chief executive officer pursuant requirements securities exchange act report signed following persons behalf registrant capacities dates indicated signature title date gorsky chairman board directors february gorsky chief executive officer director principal executive officer j caruso chief financial officer vice president finance february j caruso principal financial officer r kapusta controller chief accounting officer february r kapusta principal accounting officer c beckerle director february c beckerle coleman director february coleman davis director february davis e l davis director february e l davis signature title date l lindquist director february l lindquist b mcclellan director february b mcclellan mulcahy director february mulcahy w perez director february w perez c prince director february c prince e washington director february e washington r williams director february r williams exhibit index reg sk exhibit table description item exhibit restated certificate incorporation effective february filed document ii bylaws company amended effective january incorporated herein reference exhibit registrants form k current report filed january upon request securities exchange commission registrant furnish copy instruments defining rights holders longterm debt registrant longterm incentive plan incorporated herein reference exhibit registrants registration statement filed commission may file b form restricted shares nonemployee directors longterm incentive plan incorporated herein reference exhibit registrants form k current report filed august c form stock option certificate restricted share unit certificate performance share unit certificate longterm incentive plan incorporated herein reference exhibits registrants form k current report filed january longterm incentive plan incorporated herein reference appendix registrants proxy statement filed commission march e form stock option certificate restricted share unit certificate performance share unit certificate longterm incentive plan incorporated herein reference exhibits registrants form q quarterly report filed may f executive incentive plan amended incorporated herein reference exhibit f registrants annual report year ended december g domestic deferred compensation certificate extra compensation plan incorporated herein reference exhibit g registrants annual report year ended december h amendments certificate extra compensation plan effective january incorporated herein reference exhibit j registrants annual report year ended december certificates longterm performance plan incorporated herein reference exhibit registrants form q quarterly report quarter ended september j amended restated deferred fee plan directors incorporated herein reference exhibit k registrant 's annual report year ended january k executive income deferral plan amended restated incorporated herein reference exhibit registrants form q quarterly report quarter ended september l excess savings plan incorporated herein reference exhibit j registrants annual report year ended december amendments johnson johnson excess savings plan effective january incorporated herein reference exhibit p registrants annual report year ended december n excess benefit plan supplemental retirement plan incorporated herein reference exhibit h registrants annual report year ended january amendments excess benefit plan johnson johnson affiliated companies effective january incorporated herein reference exhibit r registrants annual report year ended december p amendment excess benefit plan johnson johnson affiliated companies effective january incorporated herein reference exhibit q registrants annual report year ended december q executive life plan agreement incorporated herein reference exhibit registrants form k annual report year ended january r executive life plan agreement closure letter incorporated herein reference exhibit registrants form q quarterly report quarter ended march johnson johnson retirement savings plan johnson johnson savings plan union represented employees johnson johnson savings plan incorporated herein reference exhibits registrant 's form filed commission may employment agreement dr paulus stoffels incorporated herein reference exhibit registrants form q quarterly report quarter ended september reg sk exhibit table description item exhibit u summary employment arrangements sandra e peterson incorporated herein reference exhibit registrant 's annual report year ended december v severance pay plan johnson johnson us affiliated companies amended restated october incorporated herein reference exhibit registrant 's form q quarterly report quarter ended september w first amendment severance pay plan johnson johnson us affiliated companies amended restated effective october incorporated herein reference exhibit registrant 's form q quarterly report quarter ended june x second amendment severance pay plan johnson johnson us affiliated companies amended restated effective october filed document statement computation ratio earnings fixed charges filed document subsidiaries filed document consent independent registered public accounting firm filed document certification chief executive officer pursuant section sarbanesoxley act filed document b certification chief financial officer pursuant section sarbanesoxley act filed document certification chief executive officer pursuant section sarbanesoxley act furnished document b certification chief financial officer pursuant section sarbanesoxley act furnished document cautionary statement pursuant private securities litigation reform act safe harbor forwardlooking statements filed document xbrl extensible business reporting language following materials report fiscal year ended january formatted extensive business reporting language xbrl consolidated balance sheets ii consolidated statements earnings iii consolidated statements comprehensive income iv consolidated statements equity v consolidated statements cash flows vi notes consolidated financial statements management contract compensatory plan copy exhibits listed provided without charge shareholder submitting written request specifying desired exhibits secretary principal executive offices company exhibit restated certificate incorporation johnson johnson pursuant section new jersey business corporation act johnson johnson restates integrates certificate incorporation heretofore amended restated read follows first name corporation johnson johnson second address corporations registered office one johnson johnson plaza new brunswick new jersey name corporations registered agent address johnson johnson third purpose corporation organized engage activity within purposes corporations may organized new jersey business corporation act fourth aggregate number shares classes stock corporation authority issue four billion three hundred twentytwo million divided two million shares preferred stock without par value four billion three hundred twenty million shares common stock par value one dollar shares class stock corporation may issued time time manner lawful consideration may time time fixed board directors case shares preferred stock board directors shall discretion determine portion consideration received shares allocate capital surplus designations preferences voting rights restrictions limitations preferred stock common stock corporation shall follows preferred stock preferred stock may issued time time board directors amounts preferred stock one series hereinafter set forth provided shares preferred stock may one time outstanding upon creation series designation rights preferences limitations description terms thereof number shares therein shall subject terms article fourth set forth amendment certificate incorporation corporation board directors hereby expressly authorized make accordance laws state new jerseyin particular without limiting general power provide rights preferences priorities inconsistent corporations certificate incorporation may permitted fixed laws state new jersey effect time creation series board directors corporation hereby expressly authorized create provide issuance series preferred stock entitling holders thereof cumulative noncumulative partially cumulative dividends b entitling holders thereof receive dividends payable parity preference dividends payable class series capital stock corporation c entitling holders thereof preferential rights upon liquidation upon distribution assets corporation convertible option holder corporation shares class classes capital stock corporation series class classes e redeemable whole part option corporation cash bonds property price prices within period periods conditions board directors shall provide including provision creation sinking fund redemption thereof f lacking voting rights limited voting rights enjoying special multiple voting rights board directors may change designation rights preferences limitations description terms number shares series shares theretofore issued b common stock shares corporations capital stock outstanding time restated certificate incorporation shall become effective shall thereupon designated common stock corporation holders common stock corporation shall entitled one vote per share common stock matters may submitted holders common stock corporation c general holder stock corporation class hereafter authorized shall right holder right board directors discretion may determine purchase subscribe otherwise acquire shares stock corporation class hereafter authorized partpaid receipts allotmentcertificates respect shares securities convertible exchangeable shares warrants instruments evidencing rights options subscribe purchase otherwise acquire shares whether shares receipts certificates securities warrants instruments unissued issued thereafter acquired corporation subject foregoing provisions article fourth board directors shall power discretion declare pay dividends upon shares stock corporation class assets corporation lawfully available payment dividends anything certificate incorporation contrary notwithstanding holder share stock corporation class shall right dividend thereon unless dividend shall declared board directors aforesaid board directors shall power provide issuance subsidiary company capital stock bonds obligations convertible option holder subsidiary company andor corporation shares class classes series class classes capital stock corporation ii right option acquire shares upon terms may fixed board directors used herein term subsidiary company shall mean corporation corporation holds directly indirectly least majority outstanding voting stock fifth number directors constituting board directors corporation current time restatement certificate incorporation twelve address director one johnson johnson plaza new brunswick new jersey names follows alex gorsky mary c beckerle mary sue coleman scott davis ian e l davis susan l lindquist mark b mcclellan anne mulcahy william perez charles prince eugene washington ronald awilliams directorship filled reason increase number directors may filled election majority directors office sixth board directors shall power make alter amend repeal bylaws corporation subject reserved power shareholders alter repeal bylaws made boardseventh proposed amendments certificate incorporation corporation shall adopted upon receiving affirmative vote majority votes cast holders shares entitled vote thereon addition class series shares entitled vote thereon class affirmative vote majority votes cast class vote eighth full extent laws state new jersey exist date hereof may hereafter amended permit limitation elimination liability directors officers director officer corporation shall personally liable corporation shareholders damages breach duty owed corporation shareholders neither amendment repeal article adoption provision restated certificate incorporation inconsistent article shall apply effect liability alleged liability director officer corporation respect act omission director officer occurring prior amendment repeal adoption ninth board directors corporation shall consist less nine eighteen members actual number determined board directors time time director corporation may removed vote shareholders except cause witness whereof johnson johnson caused restated certificate incorporation duly executed th day february johnson johnson bys alex gorsky alex gorsky presidentexhibit x second amendment severance pay plan johnson johnson us affiliated companies amended restated effective october pursuant actions pension benefits committee johnson johnson meeting held september severance pay plan johnson johnson us affiliated companies plan amended follows effective respect individuals given notice termination september article biii amended read follows eligible employee eligible benefits provided article employment terminated result one following events refusal position johnson johnson company sole discretion pension benefits committee comparable meaning new position would result reduction eligible employees base pay salary de minimis reduction pay grade eligible employees current position primary work location mile radius eligible employees current primary work location acceptance employment johnson johnson company nov lisa blair davis date lisa blair davis member pension benefits committee johnson johnson exhibit johnson johnson subsidiaries statement computation ratio earnings fixed charges dollars millions december december december january january determination earnings earnings provision taxes income fixed charges less capitalized interest total earnings defined fixed charges estimated interest portion rent expense interest expense capitalization interest total fixed charges ratio earnings fixed charges ratio earnings fixed charges computed dividing sum earnings provision taxes income fixed charges fixed charges fixed charges represent interest expense interest capitalized amortization debt discount appropriate interest factor operating leasesexhibit subsidiaries johnson johnson new jersey corporation us international subsidiaries shown january certain us subsidiaries international subsidiaries named significant aggregate johnson johnson subsidiary entity jurisdiction name subsidiary organization us subsidiaries acclarent inc delaware advanced sterilization products services inc new jersey alios biopharma inc delaware alza corporation delaware alza land management inc delaware animas corporation delaware aragon pharmaceuticals inc delaware biosense webster inc california calibra medical inc delaware cna development llc delaware codman shurtleff inc new jersey coherex medical inc delaware cordis financing corporation delaware cordis llc delaware depuy mitek llc massachusetts depuy orthopaedics inc indiana depuy products inc indiana depuy spine llc ohio depuy synthes products inc delaware depuy synthes sales inc massachusetts depuy synthes inc delaware diabetes diagnostics inc delaware ethicon endosurgery inc ohio ethicon endosurgery llc delaware ethicon llc delaware ethicon us llc texas ethicon inc new jersey heartport inc delaware jj holdings nevada inc nevada janssen biotech inc pennsylvania janssen global services llc new jersey janssen oncology inc delaware janssen ortho llc delaware janssen pharmaceuticals inc pennsylvania janssen products lp new jersey janssen research development llc new jerseyjanssen scientific affairs llc new jersey janssen supply group llc pennsylvania janssencilag manufacturing llc delaware jjhc llc delaware jnj international investment llc delaware johnson johnson middle east inc new jersey johnson johnson consumer inc new jersey johnson johnson finance corporation new jersey johnson johnson health care systems inc new jersey johnson johnson innovation jjdc inc new jersey johnson johnson international new jersey johnson johnson japan inc new jerseyjurisdiction name subsidiary organization johnson johnson services inc new jersey johnson johnson urban renewal associates new jersey johnson johnson vision care inc florida jom pharmaceutical services inc delaware lifescan inc california mcneil consumer pharmaceuticals co new jersey mcneil healthcare llc delaware mcneil mmp llc new jersey mcneil nutritionals llc delaware mentor texas lp delaware mentor worldwide llc delaware micrus endovascular llc delaware middlesex assurance company limited vermont noramco inc georgia novira therapeutics inc delaware omrix biopharmaceuticals inc delaware ortho biologics llc delaware patriot pharmaceuticals llc pennsylvania rutan realty llc new jersey scios llc delaware sterilmed inc minnesota synthes usa products llc delaware synthes usa llc delaware synthes inc delaware anspach effort llc florida international subsidiaries apsis france apsis germany gmbh germany beijing dabao cosmetics co ltd china berna rhein bv netherlands biosense webster israel ltd israel cilag advanced technologies gmbh switzerland cilag ag switzerland cilag gmbh international switzerland cilag holding ag switzerland cilag holding finance unlimited company ireland cilag pharmaceuticals gmbh switzerland cilag products gmbh switzerland cordis de mexico sa de cv mexico cordis europa nv netherlands corimmun gmbh germanycovagen ag switzerland crucell holland bv netherlands crucell nv netherlands depuy ireland ireland depuy france france depuy international limited united kingdom depuy synthes apollo limited irelandjurisdiction name subsidiary organization depuy synthes eos limited ireland depuy synthes gorgan limited ireland depuy synthes jason limited ireland depuy synthes leto sarl luxembourg ees sa de cv mexico ethicon france ethicon ireland ireland ethicon pr holdings ireland ethicon women 's health urology sarl switzerland ethnor farmaceutica sa venezuela fms future medical system sa switzerland gmed healthcare bvba belgium jc general services cvba belgium janssen alzheimer immunotherapy holding limited ireland janssen biologics ireland ireland janssen biologics bv netherlands janssen cilag farmaceutica sa argentina janssen de mexico de rl de cv mexico janssen inc canada janssen infectious diseasesdiagnostics bvba belgium janssen irish finance company uc ireland janssen korea ltd korea republic janssen pharmaceutica nv belgium janssen pharmaceutical ireland janssen pharmaceutical holdings ireland janssen pharmaceutical international holdings ireland janssen pharmaceutical kk japan janssen pharmaceutical sciences unlimited company ireland janssen rd ireland ireland janssen sciences ireland uc ireland janssen vaccine corp korea republic janssen vaccines ag switzerland janssencilag france janssencilag ab sweden janssencilag ag switzerland janssencilag norway janssencilag denmark janssencilag bv netherlands janssencilag farmaceutica ltda brazil janssencilag farmaceutica lda portugal janssencilag gmbh germanyjanssencilag kft hungary janssencilag limited thailand janssencilag limited united kingdom janssencilag nv belgium janssencilag oy finland janssencilag pharma gmbh austria janssencilag pharmaceutical saci greecejurisdiction name subsidiary organization janssencilag pty ltd australia janssencilag sa colombia janssencilag spa italy janssencilag ca venezuela janssencilag sa spain janssencilag sa de cv mexico jc health care ltd israel jjc acquisition company bv netherlands johnson johnson china investment ltd china johnson johnson china ltd china johnson johnson hong kong limited hong kong johnson johnson ireland limited ireland johnson johnson new zealand limited new zealand johnson johnson philippines inc philippines johnson johnson proprietary limited south africa johnson johnson thailand ltd thailand johnson johnson ab sweden johnson johnson ag switzerland johnson johnson belgium finance company belgium johnson johnson consumer thailand limited thailand johnson johnson consumer bv netherlands johnson johnson consumer holdings france france johnson johnson consumer services eame ltd united kingdom johnson johnson de argentina sac e argentina johnson johnson de chile sa chile johnson johnson de colombia sa colombia johnson johnson de mexico sa de cv mexico johnson johnson de venezuela sa venezuela johnson johnson del ecuador sa ecuador johnson johnson del peru sa peru johnson johnson brasil industria e comercio de produtos para saude ltda brazil johnson johnson european treasury company ireland johnson johnson finance limited united kingdom johnson johnson financial services gmbh germany johnson johnson gesellschaft mbh austria johnson johnson gmbh germany johnson johnson group holdings gmbh germany johnson johnson hellas commercial industrial sa greece johnson johnson holding gmbh germany johnson johnson holdings kk japan johnson johnson inc canadajohnson johnson industrial ltda brazil johnson johnson innovation limited united kingdom johnson johnson international financial services company ireland johnson johnson kk japan johnson johnson kft hungary johnson johnson korea selling distribution limited liability company korea republic johnson johnson korea ltd korea republic ofjurisdiction name subsidiary organization johnson johnson limitada portugal johnson johnson limited united kingdom johnson johnson llc russian federation johnson johnson luxembourg finance company sarl luxembourg johnson johnson management limited united kingdom johnson johnson medical china ltd china johnson johnson medical shanghai ltd china johnson johnson medical suzhou ltd china johnson johnson medical bv netherlands johnson johnson medical gmbh germany johnson johnson medical korea limited korea republic johnson johnson medical limited united kingdom johnson johnson medical mexico sa de cv mexico johnson johnson medical nv belgium johnson johnson medical products gmbh austria johnson johnson medical pty ltd australia johnson johnson medical sa argentina johnson johnson medical spa italy johnson johnson medical scs venezuela johnson johnson medikal sanayi ticaret limited sirketi turkey johnson johnson middle east fzllc united arab emirates johnson johnson nordic ab sweden johnson johnson pacific pty limited australia johnson johnson poland sp z oo poland johnson johnson private limited india johnson johnson pte ltd singapore johnson johnson pty limited australia johnson johnson sante beaute france france johnson johnson spa italy johnson johnson sdn bhd malaysia johnson johnson sihhi malzeme sanayi ticaret limited sirketi turkey johnson johnson swiss finance company limited united kingdom johnson johnson taiwan ltd taiwan johnson johnson uk treasury company limited united kingdom johnson johnson vision care ireland ireland johnson johnson prodaja medicinskih farmacevtskih izdelkov doo slovenia johnson johnson sa spain johnson johnson sa de cv mexico johnson johnson sro czech republic johnson johnson sro slovakiajohnson johnson medical pty limited south africa latam international investment company ireland latam properties holdings ireland lifescan france lifescan scotland limited united kingdom mcneil ab sweden mcneil healthcare uk limited united kingdom mcneil products limited united kingdomjurisdiction name subsidiary organization mcneil sweden ab sweden medos international sarl switzerland medos sarl switzerland mentor bv netherlands mentor medical systems bv netherlands mentor medical systems cv netherlands obtech medical sarl switzerland omj ireland ireland omj pr holdings ireland omrix biopharmaceuticals ltd israel pt johnson johnson indonesia indonesia shanghai elsker mother baby co ltd china shanghai johnson johnson pharmaceuticals ltd china spectrum vision limited liability company russian federation synthes suzhou medical co ltd china synthes australia pty ltd australia synthes colombia sas colombia synthes gmbh germany synthes gmbh switzerland synthes holding ag switzerland synthes limited united kingdom synthes lux finance srl luxembourg synthes luxembourg srl luxembourg synthes medical immobilien gmbh germany synthes produktions gmbh switzerland synthes tuttlingen gmbh germany tasmanian alkaloids pty ltd australia turnbuckle investment company ireland vania expansion france xianjanssen pharmaceutical ltd china xo limited united kingdomexhibit consent independent registered public accounting firm hereby consent incorporation reference registration statements form nos form nos johnson johnson report dated february relating financial statements effectiveness internal control financial reporting appears pricewaterhousecoopers llp pricewaterhousecoopers llp florham park new jersey february exhibit certification chief executive officer pursuant section sarbanesoxley act alex gorsky certify reviewed annual report fiscal year ended january report johnson johnson company based knowledge report contain untrue statement material fact omit state material fact necessary make statements made light circumstances statements made misleading respect period covered report based knowledge financial statements financial information included report fairly present material respects financial condition results operations cash flows company periods presented report companys certifying officers responsible establishing maintaining disclosure controls procedures defined exchange act rules ae de internal control financial reporting defined exchange act rules af df company designed disclosure controls procedures caused disclosure controls procedures designed supervision ensure material information relating company including consolidated subsidiaries made known us others within entities particularly period report prepared b designed internal control financial reporting caused internal control financial reporting designed supervision provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles c evaluated effectiveness companys disclosure controls procedures presented report conclusions effectiveness disclosure controls procedures end period covered report based evaluation disclosed report change companys internal control financial reporting occurred companys recent fiscal quarter companys fourth fiscal quarter case annual report materially affected reasonably likely materially affect companys internal control financial reporting companys certifying officers disclosed based recent evaluation internal control financial reporting companys auditors audit committee companys board directors persons performing equivalent functions significant deficiencies material weaknesses design operation internal control financial reporting reasonably likely adversely affect companys ability record process summarize report financial information b fraud whether material involves management employees significant role companys internal control financial reporting alex gorsky alex gorsky chief executive officer date february exhibit b certification chief financial officer pursuant section sarbanesoxley act dominic j caruso certify reviewed annual report fiscal year ended january report johnson johnson company based knowledge report contain untrue statement material fact omit state material fact necessary make statements made light circumstances statements made misleading respect period covered report based knowledge financial statements financial information included report fairly present material respects financial condition results operations cash flows company periods presented report companys certifying officers responsible establishing maintaining disclosure controls procedures defined exchange act rules ae de internal control financial reporting defined exchange act rules af df company designed disclosure controls procedures caused disclosure controls procedures designed supervision ensure material information relating company including consolidated subsidiaries made known us others within entities particularly period report prepared b designed internal control financial reporting caused internal control financial reporting designed supervision provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles c evaluated effectiveness companys disclosure controls procedures presented report conclusions effectiveness disclosure controls procedures end period covered report based evaluation disclosed report change companys internal control financial reporting occurred companys recent fiscal quarter companys fourth fiscal quarter case annual report materially affected reasonably likely materially affect companys internal control financial reporting companys certifying officers disclosed based recent evaluation internal control financial reporting companys auditors audit committee companys board directors persons performing equivalent functions significant deficiencies material weaknesses design operation internal control financial reporting reasonably likely adversely affect companys ability record process summarize report financial information b fraud whether material involves management employees significant role companys internal control financial reporting dominic j caruso dominic j caruso chief financial officer date february exhibit certification chief executive officer pursuant section sarbanesoxley act undersigned alex gorsky chief executive officer johnson johnson new jersey corporation company pursuant usc adopted pursuant section sarbanesoxley act hereby certifies best knowledge company 's annual report fiscal year ended january report fully complies requirements section securities exchange act information contained report fairly presents material respects financial condition results operations company alex gorsky alex gorsky chief executive officer dated february certification furnished sec report pursuant section sarbanesoxley act shall except extent required act deemed filed company purposes section securities exchange act amended otherwise subject liability sectionexhibit b certification chief financial officer pursuant section sarbanesoxley act undersigned dominic j caruso chief financial officer johnson johnson new jersey corporation company pursuant usc adopted pursuant section sarbanesoxley act hereby certifies best knowledge company 's annual report fiscal year ended january report fully complies requirements section securities exchange act information contained report fairly presents material respects financial condition results operations company dominic j caruso dominic j caruso chief financial officer dated february certification furnished sec report pursuant section sarbanesoxley act shall except extent required act deemed filed company purposes section securities exchange act amended otherwise subject liability sectionexhibit cautionary statement pursuant private securities litigation reform act safe harbor forwardlooking statements company may time time make certain forwardlooking statements publiclyreleased materials written oral forwardlooking statements relate strictly historical current facts reflect managements assumptions views plans objectives projections future forwardlooking statements may identified use words plans expects anticipates estimates words similar meaning conjunction among things discussions future operations financial performance companys strategy growth product development regulatory approvals market position expenditures forwardlooking statements based current beliefs expectations assumptions regarding future events statements therefore subject uncertainties risks changes difficult predict many outside company 's control investors realize underlying assumptions prove inaccurate known unknown risks uncertainties materialize actual results could vary materially companys expectations projections investors therefore cautioned place undue reliance forwardlooking statements furthermore company undertake update forwardlooking statements result new information future events developments important factors could cause companys actual results differ materially expressed implied companys forwardlooking statements follows economic factors including inflation fluctuations interest rates currency exchange rates potential effect fluctuations revenues expenses resulting margins competitive factors including technological advances achieved patents attained competitors well new products introduced competitors market share gains competitors ' branded products biosimilar generic productsstore brands challenges companys patents competitors allegations companys products infringe patents third parties could adversely affect companys ability sell products question result loss sales due loss market exclusivity require payment past damages future royalties particular firms filed abbreviated new drug applications biosimilar biological product applications fda otherwise challenged coverage andor validity company 's patents seeking market generic biosimilar forms many companys key pharmaceutical products prior expiration applicable patents covering products event company successful defending resulting lawsuits generic biosimilar versions products issue introduced market resulting potential substantial market share revenue losses impact patent expirations company 's business operating results patents expire competitors may able legally produce market similar products technologies including biosimilars generics would material adverse effect company 's sales results operations significant changes customer relationships changes behavior spending patterns purchasers health care products services including delaying medical procedures rationing prescription medications reducing frequency physician visits foregoing health care insurance coverage impact international operations financial instability international economies sovereign risk possible imposition governmental controls restrictive economic policies unstable international governments legal systems health care changes us countries resulting pricing pressures including continued consolidation among health care providers trends toward managed care health care cost containment shift towards governments becoming primary payers health care expenses laws regulations relating sales promotion reimbursement access pricing generally potential expected benefits opportunities related planned restructuring actions medical device segment may realized may take longer realize expected including due required consultation procedures relating restructuring workforce uncertainty commercial success new existing products ability company successfully execute strategic plans including restructuring plans government laws regulations affecting us international operations including relating taxes pricing reimbursement regulatory approval new products licensing patent rights environmental protection conflictminerals possible drug reimportation legislation trade monetary fiscal policies securities laws compliance competition research internally externally sourced involving development improvement new existing products processes particularly significant results time time product process obsolescence development new improved products important companys success areas business investments development commercialization collaborations externally sourced innovation inherently risky guarantee success challenges difficulties inherent product development including potential inability successfully continue technological innovation complete clinical trials obtain regulatory approvals us internationally gain maintain market approval products possibility encountering infringement claims competitors respect patent intellectual property rights preclude delay commercialization product challenges involved postmarket surveillance activities studies data collection analysis real world context product efficacy safety concerns whether based scientific evidence resulting product withdrawals recalls regulatory action part fda international counterparts declining sales significant litigation government action adverse company including product liability claims patent infringement claims antitrust claims due uncertain nature litigation government action outcome one matter may result charges excess established accruals product liability insurance products may limited cost prohibitive unavailable increased scrutiny health care industry government agencies state attorneys general resulting investigations prosecutions carry risk significant civil criminal penalties including limited debarment government business failure meet compliance obligations mcneilppc inc consent decree corporate integrity agreements johnson johnson pharmaceutical affiliates depuy synthes companies compliance agreements governments government agencies could result significant sanctions difficulties delays manufacturing internally within supply chain cause voluntary involuntary business interruptions shutdowns product shortages substantial modifications business practices operations withdrawals suspensions current products market possible civil penalties criminal prosecution interruptions breaches company 's computer communications systems company 's vendors including computer viruses hacking cyberattacks could impair company 's ability conduct business communicate internally customers result theft trade secrets misappropriation assets otherwise compromise privacy sensitive information belonging company customers business partners impact business combinations including acquisitions divestitures company well externally pharmaceutical medical devices consumer industries potential expected strategic benefits opportunities acquisition divestiture company may realized may take longer realize expected market conditions possibility ongoing share repurchase program may suspended discontinued reliance global supply chains production distribution processes complex subject increasing regulatory requirements may adversely affect sourcing supply pricing materials used products may involve multiple third parties require significant capital expenditures subject lengthy regulatory approvals financial distress bankruptcies experienced significant customers suppliers could impair ability case may purchase companys products pay products previously purchased meet obligations company supply arrangements possibility us internal revenue service could assert one contrary positions challenge transactions consummated connection acquisition synthes inc tax perspective challenged amount total purchase price synthes shares could treated subject applicable us tax approximately statutory rate company plus interest changes global climate extreme weather natural disasters could affect demand company 's products services cause disruptions manufacturing distribution networks alter availability goods services within supply chain affect overall design integrity company 's products operations impact political economic conditions due terrorist attacks us parts world us military action overseas well instability financial markets could result terrorism military actions issuance new revised accounting standards financial accounting standards board securities exchange commission foregoing list sets forth many factors could impact upon companys ability achieve results described forwardlooking statements investors understand possible predict identify factors consider list complete statement potential risks uncertainties company identified factors list permitted private securities litigation reform act